Booklet ELRIGfr Brussels 2015

ELRIGfr conference
LAB
PROCESSES
AUTOMATION
Sheraton Brussels
14 & 15 October 2015
Booklet_ELRIGfr_21.indd 1
5/10/15 06:22
ELRIGfr Committee members wish to

warmly thank the following companies who
contributed their participation and nancial
support to make this event possible:
Silver Sponsors:
Bronze Sponsors:
Event Sponsors:
- MicroTechniX
- Horizon Discovery
- BMGlabtech
- Hamilton
- Perkin Elmer
- Tecan
- Titian
- Agilent
- Argolight
- Beckman
- BioSPX
- Evotec
- GC Biotech
- Labcyte
- Lab-services
- Molecular Devices
- Ovizio
- PAA
- SAFAS
- Sopachem
- Wildcat
- Xpert Automation
- Zinsser
Invited Sponsors:
Special thanks to:
- Andaman 7
- Osimis
- Brussels Airlines
- Chocolatier Neuhaus
- HP Belgium
(& Gala Dinner Sponsor)
Booklet designed by Kevin Lewkowicz,

Brussels, September 2015.
5/10/15 06:22
Silver Sponsors
(and Gala Dinner Sponsor)
Bronze Sponsors
Sponsors
5/10/15 06:22
INDEX
Welcome ................................................... 5
The Commities ......................................... 6
The Agenda ............................................ 9
Oral Presentations ................................. 12
(Abstracts)
Posters (Abstracts) ................................ 34
Exhibitors / Sponsors ............................ 57
ELRIGfr: Mission Statement & Who we are............................... 86
Useful Information ................................. 92
5/10/15 06:22
ELRIGfr conference
LAB PROCESSES AUTOMATION
Welcome message from the
President, Olivier Casamitjana
Dear all,
It is now two years since ELRIGfr organized its founding event and we
are very happy to be back in Brussels for our 4th meeting.
The agenda is stimulating and covers many topics. I express my warmest thanks to the many speakers
who come to share with us the results of their studies. We have dedicated the meeting to 4 main themes
for us to reect on:
priate economic model? Your voice

counts, and I trust you to be very
contributive on these questions.
- Lab automation technologies

- Biological sample management
- Oncology
- Imaging
- Organising scientic and technology events for users of robotic systems, automation or lab technologies
(mainly screening, compound libraries, analytics)
- Building a network of the actors
of French speaking labs from pharma (human and animal health), chemistry, biotechnology, cosmetics and
nutrition industries as well as of academic labs with related interests
After the scientic presentations,

each session will be closed by a presentation given by one of our Sponsors, which I am happy to thank for
their continued support.
Please note that at the end of the
second day we have organized an
open forum entitled the voice of
the user. I wish you will all attend
to contribute to a general discussion
on the future of ELRIGfr. What do we
want to change? What do we want
to develop? What is the most appro-
I would also like to send a few words

to our new members and remind
everybody that ELRIGfr is a non-prot organization focused on lab automation and instruments and on
the applications of automation in a
French speaking environment. Our
main missions are:
I wish you all an excellent conference and hope to see even more of
you at our next meeting in Rennes.
Amicalement,
Olivier Casamitjana
Prsident ELRIGfr
5/10/15 06:22
Event
committee
Natalio is a Medical Biochemist who
obtained his PhD in Biochemistry
in 1984 at the University of Buenos
Aires (Argentina). He was professor of
Biochemistry in the School of Medicine of the same university until 1985.
He joined Sano in January 1986
and he continued working on the recombinant human growth hormone
developed by Sano in these years.
Some years later, he actively participated in the cloning, purication,
characterization and development of
interleukin-2 and interleukin-13 and
their receptors.
In the 90s the team developed interesting tools for the expression
cloning of receptors that have been
used with success for cytokines (IL13) and also neuropeptides such as
neurotensin and CRF.
Natalio Vita - ELRIGfr

General Secretary
(Scientic Program)
From 2004 to 2010 he was Scientic

Attach in Discovery Research Scientic Direction. For the last years and
until retirement he was Cluster Leader in E2C (Early to Candidate Unit)
in Sano, coordinating projects associated to Immuno-inammation and
Infectious Diseases.
Actually he is Editor of the Pre-Clinical Research Section in the JNHA
(The Journal of Nutrition, Health and
Aging).
Natalio is co-author of patents and
more than 60 articles covering different scientic areas like immunochemistry, biochemistry, cytokines, receptors, infection and immunity.
From 2000 to 2004, Natalio was

Head of the Cardiovascular Biochemistry group in Montpellier. The team
worked on the validation of different
targets involved in heart failure and
in the development and characterization of cardiomyocytes generated
from embryonic stem cells.
5/10/15 06:22
Pascal Silversmet
ELRIGfr VP
Relationship &
Sponsoring
Pascal Silversmet joined GlaxoSmithKline in 1995 after obtaining

his graduate in biochemistry. He
took over diverse responsibilities in
labs of R&D department. In 2000
he joined automation group and
was responsible for developing automated systems in image analysis
and microscopy eld.
Currently Pascal lead the unit Engineering Automated Systems for
Laboratory (EASy.Lab) that covers
the implementation strategy of automation transversally in R&D department of GSK Vaccines Belgium
and North America. His team activities include robotics, liquid handling and image analysis automated
systems development as well as deploy and share the automation expertise across the organization in a
partnership mindset.
Nathalie Maubon
Elrigfr CA Member Posters session
After a PhD in fundamental research

in toxicology and oncology, Nathalie
Maubon joined the Fournier laboratory where she worked for 10 years.
She set up the automation of primary screening tests in in vitro ADME
and developed all other secondary
screening tests as team leader of in
vitro ADME group. Then she took
the responsibility of a research project as a project manager. Following
a reorganization of services after the
acquisition of Fournier by Abbott,
she joined the department of in vitro
pharmacology to take responsibility
of HTS team where she developed
new HTS tests and set up the cell
imaging (HCS). After the closure of
Fournier, Nathalie took the lead of
a small CRO company, Xenoblis, as
Executive Vice-President and test
facility manager. Nathalie joined the
robotics group since 2009.
5/10/15 06:22
Jean-Marc Josse Elrigfr

Partner Speaker liaison
PhD in Molecular Biology and Plant

Cell, Jean Marc Josse has held numerous positions during his career
that led him to the position of
Country Manager of Hamilton Robotics France.
After his debut as a specialist in molecular biology is becoming Pharmacia Biotech Business Paris / northern
France. He then became responsible
for purchasing Genoscope where he
gained experience in public procurement. He then returned to the world
of commercial companies entering
in Tecan who introduced him to the
world of robotics laboratory. After a
year at Greiner Bio-One, he joined
the sales team Hamilton Robotics
France where he is today operational management.
Maria Savino - Elrigfr

Partner - Speaker liaison
Maria Savino has a Ph. D in molecular and cellular biology from Paris
University - Ren Descartes, and a
post-doctoral experience in Spain. In
2003, she obtained an MBA at ESCP
Europe Business School followed
by sales and marketing experiences
in Latin America. Back in France in
2007, she becomes Southern Europe sales manager at Cisbio. She
then joined Labcyte in 2013, and is
in charge of key accounts in France
and Benelux. Of Argentinian origin
she now lives in Avignon, France.
The marketing and logistics aspects

of the Brussels 2015 ELRIGfr conference have been taken care of by the
BoomerangForce Company.
5/10/15 06:22
ELRIGfr
conference agenda
This 2015 programme includes presentations from leading scientists
across the European Community,
covering topics such as Laboratory
Automation, Biobanking, Oncology
and Imaging.
Each conference provides a fantastic
communication and learning opportunity for scientists, whether in Academia, Biotech or Pharma.
The Lab Processes Automation
Elrigfr Conference includes a scientic poster session, networking slots,
snapshot presentations and a large
vendor exhibition.
The latter also welcomes two Belgium based startups: OSIMIS &
Andaman7.
ELRIGfr is happy to welcome them
and help them increase their visibility.
We would like to warmly thank:

The Founding Sponsors and all of
the Event Sponsors, particularly this
event with 2 Silver & 5 Bronze, for
their continued support to ELRIGfr.
And special thanks to:
Nathalie Maubon (HCS-Pharma) for
helping us set up the poster session
and Natalio Vita, ELRIGfr General
Secretary, for his huge administrative
contribution
Marc Kawam from BoomerangForce
company for his professional assistance to organise this event. Beyond
the operational aspect, his personal
commitment is much appreciated
Brussels Airlines for their support
Chocolatier Neuhaus for the tasty present in the Welcome Bags

HP Belgium for donating 2 HP ElitePad
1000 G2 Healthcare tablets
5/10/15 06:22
14th October
8h30
Welcome attendees (pastries, tea, coffee, fruit juices)
Lab Automation
Pascal Silversmet
9h15 - 9h30
Introduction by the ELRIGfr President
9h30 - 10h00
How automation changed the way we analyse

cell cultures
Prof. Gudermann, FH Bielefeld
10h00 - 10h30
Development of a High-Throughput Screening

Platform to Study the Adsorption of Antigens onto
Aluminum-Containing Adjuvants
V. Jully, GSK vaccines
10h30 - 11h00
New approach for Bioanalytical Sample preparation

with LabCyte Echo 550 M. Kapps, F. Hoffmann-La Roche, Ltd.
11h00 - 11h30
Pause: Exhibition & Posters
11h30 - 12h00
The HCS Platform at the Institut Pasteur of Lille
O. Casamitjana
A. Vandeputte, Inserm
12h00 - 12h30
Snapshots Sponsors: Beckman, Agilent, PAA, Ovizio,

Argolight, Lab-services, Osimis & Andaman7
12h30 - 14h00
Walking Lunch: Exhibition & Posters
BioBanking
Benot Fouchaq
14h00 - 14h30
Biobanks: automate or die
14h30 - 15h00
Biobank automated workows for DNA extractions
15h00 - 15h30
15h30 - 16h00
Automated sample handling in a forensic

DNA laboratory
A. Kneppers, NFI-Dutch Forensic
16h00 - 16h30
Sample Processing and Storage - RiskManagement
16h30 - 16h50
Silver Sponsor: Next generation of genetic models
16h50 - 17h50
Conseil dadministration ELRIGfr
D.Allen, IBBL
C.Mathay, IBBL
M. Bruinenberg, LifeLines, The Netherlands

B. Cross, HORIZON
10
5/10/15 06:22
Oncology
15th October
8h30
Welcome attendees (pastries, tea, coffee, fruit juices)

Natalio Vita
9h00 - 9h30
Validation of a Focused Chemical Library dedicated to

Orthosteric Modulation of Protein-Protein Interactions
using HTRF in Primary Screening X. Morelli, CNRS/CRCM
9h30 - 10h00
Bag3, a multifaceted protein playing a central

role in pancreatic cancer
M. Hahne, Montpellier
10h00 - 10h30
Quantication of cellular viability by automated microscopy and ow cytometry on the BioCell platform
A. Sauvat, IGR
10h30 - 11h00
Role of methionine sulfoxide reductase (MsrA) in

breast cancer: cellular, animal, and human studies.
11h00 - 11h30
Imaging
11h30 - 12h00
B. Favaloro, Univ. Pescara
Frederic Ausseil
Multi-application Imaging Systems Management

V. Dubois, GSK vaccines
12h00 - 12h30
Digital Pathology as a tool in tissue biomarker development for cancer immunotherapy M. Kockx, Histogenex
12h30 - 12h50
Silver Sponsor - ICARUS middleware: global management of automated systems solutions in lab processes
12h50 - 14h30
Walking Lunch: Exhibition & Posters
14h30 - 16h00
Workshop Voice of Customer All members are invited

General discussion on the future of ELRIGfr association: What do we want to change? What do we want
to develop? What is the most appropriate business
economic model?
Session will be animated by ELRIGfr Board members
16h00 - 17h00
Quiz Sponsor winner & Poster awards announcement, closing session
17h00
Verre de lamiti
W. Christiaens, Microtechnix
11
5/10/15 06:22
Lab Automation
ELRIGfr conference
ORAL PRESENTATIONS
How automation changes the way
we analyse cell cultures
Prof. Dr. Frank Gudermann, University of

Applied Sciences, Bielefeld, Germany
Some working processes in biotechnology are well automated, other

only rarely or not at all. Compared
to the automotive industry or work
ows in human diagnostic laboratories, the degree of automation in
biotechnological r&d and production is not yet complete. Nowadays,
many steps still have to be carried
out manually.
Different levels of automation of the

workow are being discussed, ranging from automation of one single
analytical method to gain precision
and accuracy to fully automated
sampling, sample handling, sample
preparation and multi parameter
analysis.
Based on the status quo of lab automation in biotechnology, concepts
for further automation are being
presented including results of a lab
automation project initiated at the
University of Bielefeld.
Examples of cell concentration determination and the measurement of

concentrations of selected analytes
in cell culture samples are used to
give an overview on the degree of
automation that has been achieved
already and to point out the benets
and limitations.
12
5/10/15 06:22
Lab Automation
Frank Gudermann
Since March 2008 Prof. Gudermann

is head of the department Technical Analytics of the study course
Biotechnology and Instrumentation
Engineering at the University of Applied Sciences, Bielefeld, Germany.
His work is focused on process analytics, process automation and optimisation of mammalian cell cultures
in lab and production scale.
Prior to his involvement in the University of Applied Sciences, he developed the Cedex analyser (1995
1998), an instrument for automated
cell concentration measurements
in samples of animal cell cultures
based on image recognition and
automated trypan blue staining.
This development led to the foundation of Innovatis AG in 1998. Dr.
Gudermann was responsible for the
strategic business development and
the product management till 2005.
In these 7 years he was able to establish the Cedex technology as
worldwide standard and developed
additional product lines, like the Cellavista or Cubian analyser.
the marketing and sales structure for

Innovatis systems, disposables and
services in North America.
Roche Applied Sciences GmbH,
Penzberg, Germany, acquired Innovatis AG in 2009.
In 2011 Dr. Gudermann and his
partner, Dr. Bodo Kohring, bought
back the Cubian product line from
Roche Applied Sciences. Together
they founded Optocell technology.
This company provides automated
biochemistry analysers, the respective chemicals and services.
From 2001 to 2005 Dr. Gudermann

was general manager of Innovatis
Inc.. Malvern, PA, USA. He set up
13
5/10/15 06:22
Lab Automation
Development of a High-Throughput Screening

Platform to Study the Adsorption of Antigens
onto Aluminum-Containing Adjuvants
Vanessa Jully, GSK vaccines, Rixensart, Belgium
Aluminum-containing salts are important adjuvants in the formulations of many licensed human vaccines. However, in the early stage
of the design of a new vaccine, a
thorough understanding of the adsorption mechanisms of an antigen
onto an aluminum salt is required.
Therefore, we have developed a robust, rapid and reproducible highthroughput screening (HTS) platform
to study the adsorption capacity of
aluminum-containing vaccines. The
adsorption isotherms on aluminum
hydroxide and aluminum phosphate
of two model proteins, -casein and
BSA, were evaluated using a liquid
handling system, which permitted
rapid sample preparation in a small
volume without non-specic ad-
sorption. Highly reproducible adsorption capacities and adsorptive

coefcients were estimated based
on the Langmuir model. To demonstrate the potential of this HTS platform, we evaluated the adsorption
isotherms for two antigens, hepatitis B surface antigen and a serotype pneumococcal polysaccharide
conjugated to a protein-D carrier,
onto aluminum-containing vaccines
at either a constant protein or a
constant aluminum concentration.
The automated assay enabled the
rapid quantication of antigen adsorption with a signicant reduction
in operator workload and reagent
use. This platform should accelerate
data acquisition during the development of a new vaccine.
Vanessa Jully
During my master degree in Pharmacy, I had the opportunity to work

in the laboratory of Professor Veronique Preat (Universit Catholique
de Louvain, UCL). Before that, I
worked during 5 months in the Department of Pharmaceutical Technology INSERM (University of Lille
II, France) directed by the Professor
Juergen Siepmann. Since two years,

I am PhD Student at GSK under a
Cooperative Research and Development Agreement with the Universit
catholique de Louvain. The subject
of my thesis is the development of
a High-throughput Screening platform for the formulation of aluminium-containing vaccines.
14
5/10/15 06:22
Lab Automation
New approach for Bioanalytical Sample

preparation with Labcyte Echo 550
Dipl. Ing. Martin Kapps, Department of DMPK and Bioanalytical R&D, F. Hoffmann - La Roche Ltd, Basel, CH
The increasing use of micro-sampling techniques in animal experimentation is challenging the

bioanalytical process.
Plasma volumes obtained using
micro-sampling techniques are
usually around 5L.
In comparison to conventional
sampling techniques where volumes are around 50L, some
compromises had to be made on
the bioanalytical processes.
Manual sample preparation is
achievable using 5L of plasma,
but in this case, treatment and extraction of the whole sample does
not allow additional measurement
(like metabolite identication) as
well as sample re-analysis.
For those reasons it is crucial to
miniaturize the sample preparation process.
Nevertheless we had to overcome

some technical hurdles to integrate
this technology into the bioanalytical sample preparation procedure.
This technique has following advantages: Only 0.5L plasma is used
from each sample for the bioanalytical analysis without any compromise on the quality of the results,
the bioanalytical sample preparation
process is now automated, and the
left over samples could be used for
additional measurements.
Our choice is to us the Echo 550

from Labcyte an instrument
able to transfer with acoustic impulse 2.5nL droplets of plasma.
15
5/10/15 06:22
Lab Automation
Dipl. Ing. Martin Kapps
Dilp. Ing. Martin Kapps is leading

the Discovery Bioanalytical Laboratory at Hoffmann La Roche Ltd in
Basel (CH) since 2011. The Laboratory is specialized in Drug quantitation for small molecules in biological
matrices arising from in vivo experiments by LC-MSMS (Liquid Chromatography coupled with Mass Spectrometer) for pharmacokinetics.
Trained in polymer Chemistry in the
Fachhochschule Aalen (D), Martin
obtained his Diplom Ingenieur FH
diploma in 1992, and after an additional specialization in Analytical
Chemistry applied to Pharmaceutical industry he obtained his Master
Degree on the Pharmaceutical University of Strasbourg (F) in 1994.
Working at F. Hoffmann-La Roche Ltd.
since 1997 in DMPK (Drug Metabolism and Pharmacokinetic) environment he was initially in charge of the
Screening Bioanalytical Laboratory
in charge to quantify small molecule
drugs levels in in vitro samples. At
this time he optimized and automated
with the Bioanalytical processes from
the laboratory to provide short response time without compromising
data quality in order to support the
Projects in early research.
16
5/10/15 06:22
Lab Automation
The HCS Platform at the Pasteur Institute

of Lille
Alexandre Vandeputte, Inserm, Lille, France
History of the settlement of a High

Content/High Throughput screening
platform at the Pasteur Institute of
Lille.
The presentation will begin with a
short overview of the Pasteur Institute of Lille environment, followed
by the review of the project:
The teams involved
The aim of the platform
The selection of the automation
The data management
Finally, some examples of screening
campaigns already ran on the platform will be reviewed and an opening on on-going projects will be
proposed.
Before joining the Pasteur Institute:

Lab automation specialist at Beckman Coulter France (Life science division)
Working at the Pasteur Institute of
Lille as a Lab automation Specialist
Engineer in charge of the robotics of
the HCS platforms located in BSL 2
and BSL 3 labs. Also in charge of the
assay optimization for automation
platform BSL 2 lab.
Joined the Institute in October 2012
to:
Review and dene the needs
Select the devices for the Screening
platform
Supervise the integration and installation
Since March 2014 (platform installed):
Maintain the system operational
Assay optimization and validation
Data management
Educational Background:
Master 2 (BAC +5) in Cellular and
Molecular Engineering (University of
Lille)
Master 2 (BAC + 5) in Automation/
Informatics (University of Lille)
17
5/10/15 06:22
Biobanking
Biobank: Automate or Die

The fundamental forces of cost
and quality push us inexorably
towards sub-contracting our
processes to machines. This is
not a goal in itself, but a means
to liberate resources and to attain
higher quality. Must everything
be automated? Certainly not, but
there is an underestimated range
of operations which today are
Dominic Allen, IBBL, Luxembourg, Luxembourg
seen as obviously manual, but which

are potentially automatable if the
processes themselves are modied.
In addition there are services which
are possible if automated, but which
are not possible manually. We will
look at automation in the context
of a biobank laboratory with a wide
range of different processes running
in parallel.
Dominic Allen
With an MBA from INSEAD and an

MA in Engineering and Economics
from Oxford, Dominic Allen acquired
20 years of experience in the elds
of nancial services, strategy consulting, and engineering. His transition
to the life science sector began 15
years ago when he became Commercial Director, then Managing Director of the Bioanalysis division of PAREXEL. Before joining IBBL as Chief
Operating Ofcer (COO), he was
Director of Bioservices at Thermo-
Fisher in Continental Europe, and

launched their commercial biorepository business.
He joined IBBL in 2009 and established the biorepository facilities. He
is now responsible for the project
management, biorepository, and
commercial activities of the organization, with a particular emphasis
on negotiating collaborative and
service contracts with partners and
clients worldwide.
18
5/10/15 06:22
Biobanking
Biobank automated workows for DNA extractions
Conny Mathay, IBBL, Luxembourg, Luxembourg
This presentation illustrates automation of nucleic acid extraction by giving details on two Biobanking workows.
The use of the chemagic MSM I
DNA extractor combined with the
Janus liquid handling station is a
robust and quick magnetic beadsbased nucleic acid extraction method which permits to process
different sample types and volumes.

We formally validated the DNA extraction workows from human blood
and stool and this presentation will
illustrate the advantages of automated sample handling and extraction of DNA from blood and stool
samples and their related formal
method validation
Conny Mathay
Connys research background is in

molecular cell biology with a specialization in dermatology. Conny holds
a PhD in Biomedical and Pharmaceutical Sciences from the University
of Namur (Belgium).
Conny accomplished Specialized
Studies in Applied Biological Sciences
(DES) including traineeships at the
Karolinska Institutet in Stockholm
and the Agricultural University of
Gembloux (GxABT).
Conny worked previously in transdisciplinary applied medical research
projects from the Rgion Wallonne.

In 2010, she joined the Integrated
Biobank of Luxembourg as Biorenery Scientist. In IBBL she is organizing and supervising activities of
the Biorenery and Biospecimen
Research laboratory and is deeply
involved in Lab Automation, Quality
Control and Validation of Analytical
Laboratory Methods. Important publications include fundamental dermatology research publications and
method validation papers.
19
5/10/15 06:22
Biobanking
An automated laboratory process for the DNA

Alexander Kneppers, NFI-Dutch Forensic,
proling of forensic samples
Den Haag, Netherlands
At the department of Human Biological Traces of the Netherlands

Forensic Institute, DNA proles are
generated from a yearly growing
number of forensic samples using
increasingly sensitive molecular methods. It is critical that throughout
the entire process of DNA proling
the sample integrity remains intact.
For the handling of forensic samples
in large quantities, sample misplacements and DNA (cross) contaminations are an increasing risk in the
process. To accomplish an efcient
work ow while minimalizing these
risks and to guarantee short turnaround times, automation of the complete laboratory process is essential.
Therefore, the NFI has implemented
a major laboratory automation program called: NFI Process Optimization DNA, or NFIPOD.
The NFIPOD program started in
2010 and was implemented in 2014.
It comprised of different projects involving the automation of the complete liquid handling process and
automated storage of trace samples
and DNA extracts. The projects were
focused on the redesign of the DNA

proling process, the development
of new solutions on automation in a
forensic setting, the integration of all
automation within the LIMS system,
and on the validation and implementation of all methods and processes.
At the basis of all automation 2D-coded tubes are used allowing for a
complete audit trail during the live
span of both trace samples and
DNA extracts. Long term storage
of all DNA-extracts for over 1 million tubes at -80 C is done in a fully
automated storage system that can
handle both trace sample tubes and
DNA extract tubes. Furthermore
liquid handlers are used for fully
automated DNA extraction, the automated setup for quantication of
DNA extracts, PCR of different genotyping systems and capillary electrophoresis.
In this presentation the NFI will
give insight in their new methods,
processes and solutions as implemented in the forensic work ow.
20
5/10/15 06:22
Biobanking
Alexander LJ Kneppers
Principle areas of interest: forensic

genetics, DNA/RNA proling, clinical genetics, hereditary diseases,
laboratory automation, LIMS, ISO
17025/15189 quality systems, technical assessor.
Alexander LJ Kneppers has held
positions in DNA/RNA proling laboratories for over 25 years. He
has worked for almost 25 years in
the department of Clinical Genetics
within the Laboratory for Diagnostic
Genome Analysis at the Leiden University Medical Center, on the development, validation and implemen-
tation of new molecular diagnostic

tools. He has a passion for human and
forensic genetics and has extensive
experience in laboratory and quality
management and IT and laboratory
automation programs. As a technical
assessor of ISO 17025/15189 quality
systems he performs assessments
in a variety of forensic and clinical
molecular laboratories at an international level. Since 2012, he holds a
position as head of the Laboratory
of DNA Proling within the Department for Human Biological Traces at
the Netherlands Forensic Institute in
the Hague, the Netherlands.
21
5/10/15 06:22
Biobanking
Sample Processing and Storage Riskmanagement
Marcel Bruinenberg, LifeLines, The Netherlands
The LifeLines project started with a

relative small pilot study in 2006. In
the mean time LifeLines has become one of the biggest longitudinal
population based studies. The aim
is to follow current included 167.000
volunteers for a period of 30 years
with respect to healthy aging. Information is collected by questionnaires and linking to external data
resources, but also during visits to
our locations in the Northern part
of The Netherlands. During these
visits blood, urine, feces and hair
samples are collected. To handle the

large amount of data and samples
the process had to be optimized
and manual processing had to be
changed to a highly automated way
of working. Automated sample processing, LIMS implementation and
automated sample storage had to
be realized. In this presentation the
process, lessons learned and some
benecial examples as well as limitations will be presented. Risk management applied during the process
will be highlighted.
Marcel Bruinenberg
Marcel Bruinenberg completed his

study at the University for Applied
Sciences (Laboratory and Process
Technologies) in 1993. Throughout
his career Marcel has been involved
in starting new laboratory facilities,
ranging from small diagnostic labs to
bigger genetic service laboratories.
Since 2006 he has been a consultant for LifeLines. Marcel accepted
a full position at LifeLines in 2008.
He started a new highly automated
Biobanking laboratory. After that he
headed the full genome analysis of
20.000 people of the LifeLines study,

served as project leader of several
add-on studies within LifeLines and
was a pioneer in services for researchers that wanted to use LifeLines
data, samples or facilities. He combined this with being project manager of LifeStore. This facility holds
one of the largest automated -80
freezer stores worldwide (> 8 million
samples) combined with 170 Ultra
low temperature freezers. Currently
Marcel is heading this facility.
22
5/10/15 06:22
Biobanking
Functional Genomics: New Horizons
With the advent of powerful new

sequencing technologies, there is a
superb opportunity to elucidate the
functional role of genes in disease.
By exploiting next generation gene
editing technologies (rAAV, CRISPR,
ZfN) Horizon Discovery has developed a large collection of stable,
modied, genetic cell line models
(X-Man) that enable researchers
to test their hypothesis and better
understand the role these genes.
These tools and others have also
powered the development of Horizons CRISPR-Cas9 functional genomic screening platform. To critically
Benedict Cross, Horizon, Cambridge,

United Kindom
evaluate the power of CRISPR-Cas9

knock-out screening in functional
genomics, we have completed several proof-of-principle and novel
screening programmes. We have
closely examined the power and applicability of the screening technologies in target ID, compound MOA
studies and patient stratication. We
conclude that CRISPR-Cas9 knockout screening offers a substantive
increment in performance over existing functional genomic screening
platforms, and if deployed astutely
can offer researchers a rapid insight
into complex biological problems.
Benedict Cross
Dr Benedict Cross is a Team Leader

at Horizon Discovery, UK. After a
PhD in Manchester, Ben trained as
a post doc with Prof. David Ron at
the University of Cambridge where
his focus was reverse chemical genetic screening. He uncovered a
remarkable new mechanism for
inhibition in the unfolded protein
response with direct applicability in
multiple myeloma treatment before
joining Horizon to expand on his
screening repertoire. Ben has continued to develop Horizons func-
tional genomic screening offering,

including arrayed RNAi and pooled
CRISPR-Cas9 platforms, and leads a
major research alliance with AstraZeneca in synthetic lethal target discovery. Bens interests are in automation and high-throughput analysis
and with a particular focus on Target
ID and Validation.
23
5/10/15 06:22
Oncology
Structure-based Guided Development &

Experimental Validation of a Focused Chemical
Library Dedicated to Orthosteric Modulation of
Protein-Protein Interactions
Xavier Morelli, CRCM/CNRS, Marseille, France
We have recently developed 2P2IDB,
a hand-curated structural database
dedicated to PPI with known orthosteric inhibitors ([1,2], http://2p2idb.
cnrs-mrs.fr). Analysis of the small molecule inhibitors present in 2P2IDB
led us to propose the rule-of-four
as a guideline to characterize PPI
inhibitors [3]. Using dedicated support vector machine approaches,
we have developed 2P2IHUNTER, a
tool for ltering potential orthosteric
PPI modulators from large collection of compounds [4]. This innovative tool has been applied to a set
of 8.3 million compounds from the
big vendors to design several in
silico PPI-focused chemical libraries
[5]. Compounds corresponding to
medicinally important privileged
structures identied as core structures in numerous therapeutics were
prioritized in a medicinal oriented
version of the library. The library was
ltered with carbon bond saturation
index (Fsp3) to escape from atland,

which resulted in a structurally diverse chemical library, 2P2I3D, of
1,664 compounds [5]. The molecules have been purchased from the
providers, stored in 384-well plates
and evaluated using Homogeneous
Time-Resolved Fluorescence spectroscopy ( HTRF ) on the AD2P Platform ( part of the National Network
of the French Screening Platform,
Marseille ) and in collaboration with
several Biotech companies against
a standard set of PPI targets ( P53/
MDM2 ; TCF/catenin ; BRD4 Bromodomain; PDZ domains and viral
PPIs) to evaluate their ability to enhance hit rates in general screening
campaigns (2P2IHTS Program). The
design and molecular properties of
the in silico chemical library and the
HTS results will be discussed during
this presentation with a specic emphasis on Bromodomains and PDZ
domains.
References
[1] Bourgeas, R., et al. 2010. PLoS ONE, 5 (3), e9598.
[2] Basse, MJ., et al. 2012 Nucleic acid research, Jan;41(Database issue):D824-7.
[3] Morelli, X., Bourgeas, R., Roche, P. 2011. Curr Opin Chem Biol. 15, 1-7.
[4] Hamon V., et al. 2013. Journal of the Royal Society, Interface Nov 6;11(90):20130860.
[5] Hamon V., et al. 2013. Med. Chem. Commun.,4, 797-809
24
5/10/15 06:22
Oncology
Xavier Morelli
Group Leader of the Laboratory of integrative Structural & Chemical Biology (iSCB, http://iscb.cnrs-mrs.fr).
Director of the Molecular Modeling
Platform INT-3D (http://int3d.cnrsmrs.fr)
National Secretary of the French Society of Chemoinformatics (SFCi).
Member of the National Scientic
Committee of the ARC (Association
for the Research against Cancer)
Associate Editor of BMC Pharmacology & Toxicology.
49 Research Articles. 1 book chapter.

2 international patents.
50 invited Conferences since 2006
(25 international conferences/seminar).
Advisor of 6 PhD students since 2006.
Consulting for pharmaceutical companies since 2009
Expert for several national agencies
(Ireland, Netherland, Singapore,
France)
Awarded >11 national & international grants since 2010
25
5/10/15 06:22
Oncology
BAG3, a multifaceted protein playing a central

role in pancreatic cancer
M. Hahne, IGMM/CNRS, Montpellier, France.
The incidence and death rate of
Pancreatic Ductal Adeno Carcinoma (PDAC) has increased in recent
years, therefore the identication
of novel targets for treatment is
extremely important. Interactions
between cancer and stromal cells are
critically involved in tumor formation
and development of metastasis.
Here we report that PDAC cells secrete the co-chaperone BAG3 (Bcl2 associated athanogene 3), which
binds and activates macrophages,
inducing their activation and the se-
cretion of PDAC supporting factors.

We also identify IFITM-2 as a BAG3
receptor and show that it signals
through PI3K and the p38 MAPK
pathways. Finally, we show that the
use of an anti-BAG3 antibody results in reduced tumor growth and
prevents metastasis formation in
different mouse models. In conclusion, we identify a paracrine loop
involved in PDAC growth and metastatic spreading, and show that an
anti-BAG3 antibody has therapeutic
potential.
Michael Hahne
University Education:
1989: Diplom in chemistry and biochemistry; Max-Planck-Institute for
Immunobiology in Freiburg (Germany)
1993: PhD in biochemistry; Biozentrum at University of Basel (Switzerland)
Professional Cursus:
1994: Postdoc in the group of Prof.
Tschopp; Institute of Biochemistry at
the University of Lausanne (Switzerland)
1999: Group Leader at the Department of Immunology & Oncology in
the Centro Nacional de Biotecnolo-
ga (CNB) in Madrid, Spain

2003: Directeur de Recherche and
group leader at the IGMM
2013: Guest professor at the University of Chieti (Italy)
Scientic interest:
Our group (http://www.igmm.cnrs.fr/
spip.php?rubrique32) has a long-standing interest in the role of TNF family
members in disease, with a particular focus on colorectal cancer, autoimmunity and inammation. This
expertise led to the development of
new research projects, such as the
role of BAG3 in tumorigenesis.
26
5/10/15 06:22
Oncology
Quantication of cellular viability by

automated microscopy and ow cytometry
Allan Sauvat, IGR, Villejuif, France
on the BioCell platform
Cellular viability is usually determined by measuring the capacity
of cells to exclude vital dyes such
as
4',6-diamidino-2-phenylindole
(DAPI), or by assessing nuclear
morphology with chromatinophilic
plasma membrane-permeant dyes,
such as Hoechst 33342. However, a
fraction of cells that exclude DAPI or
exhibit normal nuclear morphology
have already lost mitochondrial functions and/or manifest massive activation of apoptotic caspases, and
hence are irremediably committed
to death. Here, we developed a
protocol for the simultaneous detection of plasma membrane integrity
(based on DAPI) or nuclear morphology (based on Hoechst 33342), mitochondrial functions (based on the
mitochondrial transmembrane potential probe DiOC6(3)) and caspase
activation (based on YO-PRO-3,
which can enter cells exclusively
upon the caspase-mediated activation of pannexin 1 channels). This
method, which allows for the precise
quantication of dead, dying and
healthy cells, can be implemented
on epiuorescence microscopy or
ow cytometry platforms and is
compatible with a robotized, highthroughput workow.
Allan Sauvat
Allan Sauvat received his engineers

degree in 2011 from the Institut
Suprieur de BioSciences in Paris,
France. He is now a research engineer on the BioCell platform in
Villejuif, France, where is focusing
on HTS assay and software development for systems biology.
27
5/10/15 06:22
Oncology
Role of methionine sulfoxide reductase (MsrA) in

breast cancer: cellular, animal, and human studies
Bartolo Favaloro, UNICH, Pescara, Italy
Redox signalling and oxidative stress

has been recently implicated as an
important regulator of tumour cell
survival, proliferation and invasion.
The most prominent ROS in cell signaling is hydrogen peroxide, which
acts mainly through oxidation of
cysteine and methionines of target
proteins. Our goal is to understand
the role of methionine sulfoxide reductase A (MsrA) in the biology of
breast cancer. MsrA is considered a
ROS scavenger, and one of the major enzymes able to reduce methionine sulfoxide moieties (MetO). The
cyclic interconversion of Met and
MetO residues of proteins is involved in several different biological
processes such as scavenging of
ROS, regulation of enzyme activities,
and cell signalling.
One of the most important causes
of poor prognosis in cancer patients
is tumour cell invasion of distal or-
gans, followed with the formation of

metastases. We demonstrated that
MsrA-silenced breast cancer cells
showed a more invasive ROS-dependent phenotype. Indeed, we
showed that loss of MsrA exerts
its effects through both a ROS-dependent activation of the phosphoinositide 3-kinase (PI3K) pathway
and increased production of vascular endothelial growth factor (VEGF).
The underlying molecular mechanisms involve increased H2O2 levels, resulting in the reduction of
phosphatase and the deletion tensin homolog on chromosome ten
protein (PTEN), and the activation
of the PI3K-pathway. In addition,
we showed that MsrA expression is
down-regulated in a subset of human breast cancer tissues, and the
MsrA mRNA levels correlate inversely with histological nuclear grade.
28
5/10/15 06:22
Oncology
Bartolo Favaloro
My research career began in 1993 as

a research appointment at Mario Negri Sud where I started working on
elucidating the mechanisms of action of detoxication enzymes involved in the metabolism of xenobiotic
molecules and in the oxidative stress
in microorganisms. This involved the
role of bacterial glutathione transferases and methionine sulfoxide
reductase A (MsrA) enzymes in the
cellular detoxication system, and

the involvement of these enzymes in
the bacterial drug-resistance.
Since 2004 I have lead an independent research group in the Center of Excellence on Aging (CESI)
within the University of Chieti-Pescara, focused on both role of MsrA
and alteration of redox signalling in
cancer cells.
29
5/10/15 06:22
Imaging
Multi-application Imaging Systems Management
Vincent Dubois, GSK, Rixensart, Belgium
Multi-application imaging systems

in GSK are the result of more than 10
years of improvement. The number
of systems and users was increasing
exponentially and it was not sustainable to manage 1 system for 1
process type. We needed to reduce
cost, decrease lab space and standardize time for implementation. No
commercial solution available on the
market conducts us to develop our
specic tools:
- To calibrate the systems and ensure
the intra/inter-reproducibility (light
source and camera calibration).
- To make the link between scientists
expertise and technology, reducing

time for conguration setup and validation (Teaching application)
- To manage the routine readout:
different tests within the same run,
ensure data integrity (Reading application)
- To manage efciently the automated systems park: hardware conguration, image analysis protocol,
user access management (Global
Layer Management)
All these key elements allowed us
to design an end-to-end solution to
control complex processes, from right
image acquisition to nal results.
Vincent Dubois
Vincent Dubois is Project Manager

- Image Analysis systems in EASyLAB team (Engineering Automated
Systems for Laboratories) that covers automation transversally in R&D
department of Glaxosmithkline Vaccines. He started his career in GSK
as lab technician in QC department
after studying biotechnology and
agro-industry. He joined the Automation Team in 2001 where he developed hardware and software of
image analysis systems.
From this time, he had the opportunity to install automated systems
in different laboratories of R&D and

QC department, at a global level,
ensuring the development, installation, validation (till GMP level), support and life cycle management.
He mainly developed specic applications/systems for bacteriology,
virology and formulation laboratory
processes.
Areas of interest: image processing,
microscopy, optics, acquisition devices, validation, IT, programming,
robotics
30
5/10/15 06:22
Imaging
Digital Pathology as a tool in tissue biomarker development

for cancer immunotherapy
Mark Kockx , Histogenex, Antwerp, Belgium
The revolutionary conuence of
immuno-oncology has stimulated
an insistent demand for describing
the activity of immune inltrates in
concert with the tumors evolution
and its micro-environment. The response has been an equally revolutionary outpouring of histo-pathology
and molecular biomarker methodologies. This has in turn created a
need to integrate the morphological
information with molecular data and
the subsequent modeling and regression of this data.
HistoOncoImmune is a biomarker methodology that HistoGeneX

has developed to support the clinical development of immune-oncology programs. The methodology
harnesses intelligent and robust technologies to integrate histo-pathology
and molecular data for the purposes
of hypotheses generation and patient
enrollment efforts. The use of digital
pathology combined with image analysis for the quantication of cytotoxic
T cells in tumor tissue will be demonstrated during this presentation.
Mark Kockx
Dr. Mark Kockx was trained as an

Anatomic Pathologist and founded
Histogenex Laboratories in 2001. At
the University of Antwerp, Belgium,
Dr. Kockx pioneered methodologies
to elucidate apoptotic and cytostatic response of cancer patients after
treatments with targeted therapies.
His subsequent collaborations with
global pharmaceutical companies
led to the founding of Histogenex
Laboratories.
Dr. Kockx is an internationally recognized pathologist-scientist who has
operated on the forefront of personalized medicine developments.
He continues to lead initiatives to
standardize biomarker analysis practices in addition to adapting novel

technologies. Dr. Kockx has been
extensively involved with the clinical trials that led to the approval
of well-known targeted therapies
such as EGFR, BRAF and MEK inhibitors. His current passions are two
fold. He is introducing practices and
workows for next generation IHC,
combining innovations of multiplex
staining, quantication and image
capture. He has also developed an
Immunomics program, a state of the
art biomarker program that supports
the evolving and numerous needs of
immunotherapy development.
31
5/10/15 06:22
Imaging
ICARUS middleware: global management

of automated systems solutions
Wouter Christiaens, Microtechnix,
in lab processes
Sint-Niklaas, Belgium
MicroTechniX main eld of activity

is integrated imaging analysis solutions, global layer management,
quality & validation management.
Our strategy is to create end to
end solutions, integrated in your lab
processes, with a strong partnership
mind-set. This partnership is key
with the nal end user but also with
our own suppliers.
During this talk, we will explain our
partnership business model to get
the expert extended capacity to
build solution on time, ensure quality management and ensure life cy-
cle management of your systems.

The second part of the talk will focus
on our capacity management platform ICARUS.
The ICARUS platform is an intuitive
middleware interface that manages
instruments and their applications,
connect them to users and plan /
manage the use of it across all environments.
The management of the Robotic Liquid Handler from TECAN will be
presented as a case study.
www.microtechnix.com
++32 (0)3 780 30 01
infoa@microtechnix.com
32
5/10/15 06:22
Imaging
Wouter Christiaens
After graduating from the Maritime

Institute De Ruyter Netherlands
Wouter started his career in a few
smaller companies. Technology has
a central place in his life so it did not
take long before the company Carl
Zeiss took an interest in him and offered a position as engineer for the
service of high-end microscopes.
Following his career at Carl Zeiss
he held positions as account manager, responsible for several regions
in Belgium and Project Manager of
complex systems for the Benelux.
In this period he completed the studies for system analyst-programmer,
sales expert (KennethSmith) and
sales management.
After more than 15 years working

for the company Carl Zeiss, Wouter
started in 2013 the company MicroTechniX with the moto "a no is
not an answer" and created a team
that is committed in realizing all the
challenges they receive in the elds
of development, life cycle management, integrated solutions for image
analysis, global layer management,
quality management and validation.
"We offer creative and sustainable
solutions, not by focusing on how
good we are in one discipline, but
how good we are bringing together
different expert disciplines," quote:
Wouter
33
5/10/15 06:22
ELRIGfr conference
POSTERS
ABSTRACTS
34
5/10/15 06:22
P1 Argolight
P2 Eurons
P3 Hamamatsu
P4 Hamamatsu
P5 Hamamatsu
P6 HCS Pharma & Perkin Elmer
P10 Inventiva
P11 Labcyte
P12 Labcyte
P13 Molecular Devices
P16 OVIZIO
P17 Perkin Elmer
P18 Pikairos
P19 Sano Aventis
P20 UCB
P21 University of Lige
35
5/10/15 06:22
P1: Argolight
Towards automating performance assessment, monitoring,
and quality control of uorescence imaging systems with
Argolight solutions
Arnaud Royon, Gautier Papon
Argolight SA, Domaine du Haut Carr, Building C5, 351
Cours de la Libration, F-33405 Talence, France
Email: a.royon@argolight.com
We present a new tool for performance

assessment,
monitoring and quality control of uorescence-based
imaging
systems
(wide-eld, confocal, multiphoton,
high content screening machines),
based on long term stable uorescent patterns with sub-micrometer
feature sizes embedded in glass in
3D. This new solution, consisting in
test slides accompanied with dedicated image analysis algorithms,
enables the assessment of almost
all the aspects of a uorescence
imaging system: eld deformation,
stage repositioning accuracy, de-
tector characteristics, illumination

homogeneity, spatial resolutions,
and response in terms of spectrum,
intensity and lifetime. In addition
to uorescence, the same patterns
exhibit contrast in bright and dark
elds, DIC, and phase, which makes
them also suitable to assess these
types of microscope. Because Argolight slides are durable, they allow
to follow the evolution of the system
performance over time, and to setup a fully-automated quality control
by integrating the image analysis
algorithms in the machines control
software.
36
5/10/15 06:22
P2: Eurons
High throughput label free identication of inhibitors of
writers and erasers of acetyl groups
Manilduth Ramnath, Wassim Kaaki, Chantal Rein, Chrystle Ayrald Bessieres,

Christelle Geffard, Fabien Pillorger, Benot Fouchaq
One of the rst histone post-translational modications to be identied and

studied was histone lysine acetylation.
Histone acetyltransferases (HAT) are
responsible for the addition of an acetyl
group to the lysine residues in the N-terminal tail and on the surface of the nucelosome core of histone proteins. Histone-deacetylase (HDAC) on the other
had remove acetyl groups. Acetylation
is generally associated with transcriptional activation, whereas lack of acetylation tends to correlate with repression,
the destabilization of this equilibrium
has been correlated to several disease
states. The identication of inhibitors of
both HAT and HDAC families are been
actively pursued by the pharmaceutical

industry.
We have screened a peptide library of
acetylated histone peptides in order to
identify the most biologically relevant
substrates for HDACs and Sirtuins. We
have subsequently, established a high
throughput screening (HTS) compatible
assays for 6 HDACs and 3 Sirtuins. On
the other hand we have also, established a single HTS compatible method
for monitoring of the enzymatic activity
of all members of the HAT family using
variable complex substrates. Both methods have been set-up and optimized
on an Aglient RapidFire 365 coupled to
a QTOF 6550.
37
5/10/15 06:22
P3: Hamamatsu
Use of High Throughput Electric Field Stimulation (EFS)
Coupled with Intracellular Ca2+ Kinetics Measurements on
iPSC-Derived Cardiomyocytes
Sunao Hisada, Natsumi Kato, Masanobu Matsubara, Takuji Kataoka
(Hamamatsu Photonics K.K. Systems Division, Hamamatsu City, Shizuoka Pref, Japan)
Ralf Kettenhofen and Felix von Haniel
(Axiogenesis AG, Nattermannallee 1, 50829 Cologne, Germany)
Jean Marc dAngelo
(Hamamatsu Photonics France)
Hamamatsu has developed a

96-channel electrode array system
that is mounted on the FDSS/CELL.
It adds electric eld stimulations
(EFS) to all 96 wells in a microplate
simultaneously while uorescence/
luminescence signals are monitored.
We measured oscillations of intracellular Ca2+ concentration, which
occurs along with the beating of the
cells, with a calcium sensitive uorescent dye in human iPSC-derived cardiomyocytes (Cor.4U, Axiogenesis
AG). We observed that the Ca2+
oscillation in cardiomyocytes was
synchronized to the electric stimu-
lation, which indicates that the EFS

system is able to pace the beating of
cardiomyocytes. We also observed
that the Ca2+ oscillations in the presence of some ion channel blockers
were modulated by adding EFS.
Use of EFS coupled with intracellular Ca2+ kinetics measurements, in
the high-throughput manner, should
be useful in in vitro assessment of
cardiac toxicity of pharmacological
compounds using cardiomyocytes,
in particular in toxicity screening at
early stages of drug development,
as well as in cardiomyocyte research.
38
5/10/15 06:22
P4: Hamamatsu
BRET2 assay using the FDSS/CELL: monitoring cellsurfacereceptor internalization and intracellular trafcking Cellular
Frederic Finana, Luc De Vries (Cellular and Molecular Biology, Pierre

Fabre Research Institute, Castres, France)
Jean Marc dAngelo (Hamamatsu Photonics Europe GmbH)
After the publication of application

note n23 describing BRET1 technology and based on a study published in 2011, Pierre Fabre Research
Institute recently implemented the
more sensitive BRET2 technology to
the FDSSCell system for monitoring the internalization of the human

dopaminergic D2s receptor, a prototypic G protein-coupled receptor
(GPCR). The result of this work will
be present.
39
5/10/15 06:22
P5: Hamamatsu
Optogenetics: A Bright Future for Voltage Gated Ion
Loredana Redaelli, Jean-Francois Rolland, Lia Scarabottolo, Viviana

Agus, Stefan Lohmer (AXXAM SpA, Milano, Italy)
Annamaria Mauro, Laura Confalonieri (Hamamatsu Photonics Italia srl)
Jean Marc dAngelo (Hamamatsu Photonics France)
Channels Channelrhodopsin-2 (ChR2)

is a light-activated microbial cation
channel which can be used to depolarize neurons through the incidence
of blue light (470 nm).
The possibility to optically control
the plasma membrane voltage opens
new and interesting perspectives for
the characterization of voltage-gated
ion channels and the search for modulators.
Proof of principle studies have been
performed to verify the applicability
of this tool for the development of
cell based assays in High Throughput
Screening (HTS) platforms as microplate readers.An HEK-293 cell
line, which stably co-expresses the
human voltage-gated calcium channel hCav1.3 and the inward rectier
hKir2.3 channel, was over-transfected
with a ChR2 carrying a single amino
acids mutation.
This latter result in a prolonged lifetime of the conducting state of ChR2
and in a reduced light power requirement for its activation.
A protocol of light stimulation of
ChR2 and record of calcium ion inux through Cav1.3 with the use of
a calcium-sensitive uorescent dye
(Fluo8) was tested in the Hamamatsu FDSScell. A well-known Cav1.3
blocker, Isradipine, tested in the
resting and the partial inactivated
Cav1.3 states, was used to conrm
the pharmacological prole.Data obtained for the ChR2/hCav1.3 cell line
by light stimulation have been also
compared to the extracellular potassium stimulus and to patchclamp to
cross-check their reliability.
40
5/10/15 06:22
P6: HCS Pharma & Perkin Elmer

Development of a neuroproctection assay for Parkinsons
disease in vitro model using HCS
Maubon Nathalie1*, Roudaut Meryl1, Alioune Ndoye2, and Bursztyka Julian1

1
HCS Pharma, 6 rue Pierre Joseph Colin, 35000 RENNES
2
Perkin Elmer, 16 av Qubec, 91140 VILLEBON SUR YVETTE
1*
nathalie.maubon@hcs-pharma.com
Parkinsons disease (PD), a neurodegenerative disorder, is caused by

the death of dopaminergic neurons
in the substantia nigra. High content
screening (HCS) should allow nding
new pathways involved in the onset
of PD by screening molecules based
on phenotypes related to cell death.
Rotenone, a chemical compound
commonly used as a pesticide, is
well-documented as a cell death inducer of dopaminergic neurons in
the substantia nigra and allows mi-
micking PD in vitro and in vivo.

HCS Pharma is working to develop
new, more complex and relevant in
vitro cellular models that mimic the
pathology as closely as possible. In
this poster, a neuroprotection model of PD is presented, with differenciated SH-SY5Y neuronal cells,
exposed to rotenone. Model was
developed in 2D culture and rst
results in 3D culture are also presented.
41
5/10/15 06:22

High Content Screening of automated wound healing and
cytotoxicity assays in 2D and 3D culture
Maubon Nathalie1*, Roudaut Meryl1, Alioune Ndoye2, and Bursztyka Julian1

1
2
1*
nathalie.maubon@hcs-pharma.com
To nd anti-cancer drugs, different

cellular modication can be looked
at: cell death effect on proliferating
cells either in 2D culture or on spheroids (3D culture), anti-mitotic, anti-migration/invasion, anti-angiogenesis effects Different assays can
be performed to follow these different effects. High content screening
is a multi-parametric technology
allowing searching for poly-effects

drugs.
In this poster, 8 well known compounds were tested in 3 different assays: cytotoxicity in 2D culture, cytotoxicity in spheroids (3D culture) and
scratch assay (also named wound
healing). These 3 models were automated in 96-well plates. Results are
shown and discussed in this poster.
42
5/10/15 06:22

HepG2 cell model for steatosis and phospholipidosis
assessment by high content analysis
Bursztyka Julian1*, Roudaut Meryl1, Alioune Ndoye2, and Maubon Nathalie1

1
2
1*
julian.bursztykan@hcs-pharma.com
In order to avoid late and expensive

attrition rate due to toxicity side effects, early assays are mandatory.
High content analysis has the advantage to enable multiplexing: one
assay allows the analysis of several
read-outs. Despite its lack of several normal hepatocytes fonctions,
HepG2 in 2D or 3D culture can
be used with advantages in some

cases. HepG2 cells have been exposed to rifampicin, ticlopidine, cyclosporine A, sertraline, amiodarone
and ketoconazole for 48h. Cell viability, steatosis and phospholipidosis
were then assessed by high content
analysis. Results are shown and discussed in this poster.
43
5/10/15 06:22

Genotoxicity assays: assessment of double strand breaks
through phospho-H2AX detection and micronuclei analysis in
high content screening
Bursztyka Julian1*, Roudaut Meryl1, Alioune Ndoye2, and Maubon Nathalie1

1
2
1*
julian.bursztykan@hcs-pharma.com
Among DNA damages, DNA

double-strand breaks (DSBs) are
considered the most dangerous.
DSBs may be encountered in response to exogenous stimuli, and
triggered either by ionizing radiations or DNA-damaging chemicals.
It is therefore mandatory to assess
eventual genotoxic properties of
therapeutic and cosmetic molecules
in the early phase of research, to
avoid late attrition. In response to
DSBs, H2AX is phosphorylated within minutes at Ser 139, and is then
referred as H2AX. Because phosphorylation of H2AX in response to
DSBs is fast, abundant and mostly
specic, it is the most interesting
marker that can be measured to follow DSBs formation and DNA repair.
Contrary to H2AX, micronuclei are
a late marker of damages either to
DNA but also to the spindle apparatus. They are formed after exposure
of the cells to a test substance, followed by a mitosis cycle. Damages
to DNA or to the spindle apparatus can result in the formation of a
smaller micronucleus, apart from the
main nucleus, that can be detected
in HCS.
Here we will present the H2AX and
micronucleus assays on HT29 and
HeLa cell lines. Results expressed as
foci count and mean nuclei H2AX
intensity will be compared.
44
5/10/15 06:22
P10:
Inventiva Pharma
A rational approach for the discovery of inhibitors of NSD2

for the treatment of cancer
Xavier Espanel, Sverine Estevez, Vanessa Adarbes, Stphanie Bocart, Bruno

Loillier, Florence Chirade, Sbastien Jacquet, Anne Soud, Philippe Masson,
Bruno Bournique, Christine Massardier, Fabrice Guillier,
Benassa Boubia, Christian Montalbetti, Pierre Broqua and Claudia Fromond
Inventiva Pharma, Daix, France
Jason Davenport, Aaron Martin and Eric Reese
SensiQ, Oklahoma City, OK 73104, USA
Multiple myeloma (MM) is a plasma

cell malignancy which accounts for
approximately 10% of hematologic
malignancies. Despite the introduction of new therapeutic agents,
MM remains incurable and nearly all
patients ultimately relapse. About
20% of MM are due to a chromosomal translocation t(4;14) leading to
overexpression of the NSD2 histone
methyltransferase. NSD2 catalyzes
dimethylation of lysine 36 on histone H3 (H3K36me2) and is associated with transcriptionally active
regions. Several studies have shown
that in MM harboring the translocation t(4;14), oncogenic programming is dependent on the methyltransferase activity of NSD2. In addition,
the NSD2 overactivity is also observed in prostate and lung cancers.
Thus, NSD2 is a potential target for
cancers, for which no selective drug
is available to date.
Using the AlphaLisa technology,
we screened 240,000 compounds
coming from our proprietary library.

The assay is based on the detection
of H3K36me2 on nucleosome by a
specic antibody. False positives
hits were removed by a technological counterscreen, and compounds
with redox activity were excluded.
This strategy allowed us to identify
about 200 compounds. To focus on
the most interesting ones, an orthogonal counterscreen based on 3H
SAM incorporation has been setup. In parallel to the biochemical
screening, binding of hits to NSD2
protein were conrmed by SPR. To
our knowledge, no NSD2 inhibitor
have been identied to date despite several screening effort performed by other groups. Our library
has already produced new chemical starting points for other KMTs,
and we believe that our hits could
be promising starting points to generate potent and selective NSD2
inhibitors.
45
5/10/15 06:22
P11: Labcyte
Evaluation of combination treatment efcacy utilizing the
Labcyte Echo liquid handler and Echo Combination
Screen Software reduces cost and increases exibility in a
PC3 prostate cell viability assay
Aurore Lejeune-Dodge1, Linda Orren1, Tim Allison1,

John Lesnick1, Carl Peters2,
1
Labcyte Inc., Sunnyvale, CA, USA;
2
BMG LABTECH, Cary, NC, USA
Class I PI3Ks have been extensively

characterized with respect to their
roles in cell proliferation and tumorigenesis, and therefore serve
as desirable targets for oncogenic
drug development. Class I PI3K
isoform-specic inhibitors provide
elucidation of the individual isoform
functionality, and on the dependence of particular cell types upon
them. In this study, we evaluated the
impact of PI3K isoform-selective inhibitors on the viability of PC3 prostate cancer cells, which lack PTEN
tumor suppressor regulation. By
determining the potency of singleagent and combined isoform-selective inhibitors, the cellular reliance
on the functionality of individual isoforms can be evaluated.
Utilizing the Labcyte Echo 555 liquid
handler and the recently released
Echo combination screen software
(ECS), we have demonstrated a
highly efcient, robust assay to evaluate the impact of PI3K inhibitors
on PC3 cell line viability. The Echo
555 series liquid handler system uses
direct dilution to dispense nanoliter

volumes of inhibitor compounds at
high concentrations to assess dose
dependent effects on cell viability
as single agents and in combination
treatment (CT). Additionally, the
employment of our ECS Software
compliments CT protocols by providing a graphical interface to visually combine dose-response curves,
controls, and single concentration
transfers into one combination
screening protocol. The synergistic
or additive efcacy of the combination treatment with PI3K pathway inhibitors in combination studies were
assessed relative to single agent
treatment. Utilization of ECS to deliver combinations of inhibitors to
the assay plate greatly facilitates the
execution of a complex design and
produces compelling data. The Labcyte Echo liquid handlers and ECS
software enable rapid and robust
assay execution to effectively inform
the biological rationale for use of
the combination treatment.
46
5/10/15 06:22
P12: Labcyte
Identication of HDAC1 inhibitors with an automated
Fluorogenic assay using the Labcyte Access Workstation
with an integrated Labcyte Echo Liquid Handler and
Echo Qualied Reservoir
Aurore Lejeune-Dodge1, Linda Orren1,

Bonnie Edwards1, John Lesnick1, Carl Peters2
1
Labcyte Inc., Sunnyvale, CA, USA ;
2
BMG LABTECH, Cary, NC, USA
Epigenetics continues to emerge as

an important target class for drug
discovery and cancer research. As
programs scale to evaluate many
new targets related to epigenetic expression, new tools and techniques
are required to enable efcient
and reproducible high-throughput
epigenetic screening. Echo liquid
handlers can transfer compounds,
samples, and reagents in sub-microliter volumes to high density assay
formats using only acoustic energy
- no contact or tips required. This
eliminates tip costs and reduces the
risk of reagent carryover. Employment of our newly-released Echo
qualied reservoir enables rapid
delivery of common reagents to an
assay plate using the precision of
acoustic energy. Additionally, use of
the BMG PHERAstar FS multi-mode
plate reader, with the highest sensitivity and lowest read time of assays in high density plate formats,
is a perfect complement to enable
an unparalleled solution for cost-ef-
fective, high-throughput epigenetic screening. The Labcyte Access

Workstation greatly facilitates assay
execution to identify epigenetic inhibitors by integrating the Echo liquid handler, the Pherastar , as well
as a bulk dispenser, a centrifuge and
a plate sealer and peeler.
Using Enzo Life Sciences Fluor de
Lys technology, we developed a
deacetylase assay that can be miniaturized and easily adapted to automation to produce high data quality.
The Fluor de Lys assay is typically
performed at a 100 L volume in
96-well format. However, with the
nanoliter dispense increments of
the Echo liquid handler, assay volumes can be reduced signicantly
while maintaining data quality. In
this study we were able to develop
a robust, automated 384 well deacetylase assay in a 3 L nal volume
that produced potency results for
known HDAC1 inhibitors that are in
good agreement with published literature values.
47
5/10/15 06:22
P13: Molecular Devices

Development of a cell-based potassium-chloride transporter
assay using a new FLIPR Potassium Assay Kit
Andrea Townsend-Nicholson & Stephanie Schorge; University College

London and Simon Lydford; Molecular Devices (UK) Ltd
Potassium-chloride transporter member

5 (KCC2) is one of nine cation-chloride cotransporters (CCCs) encoded
by the SLC12 family of genes, and
is the only CCC transporter preferentially expressed in neurons. KCC2
plays a critical role in the correct functioning of the CNS where it is pivotal
in maintaining neuronal intracellular
Clconcentration ([Cl]i). KCC2 is
involved in the control of numerous

neuronal processes and its impaired
activity has been identied in epilepsy, neuropathic pain and spasticity
following spinal cord injury. This suggests that positive modulators of the
activity of expression of KCC2 may
provide effective therapy for neuronal conditions arising from defects in
KCC2 functionality.
48
5/10/15 06:22

Development of a platelet calcium ux assay using Fura-2,
AM on the FlexStation 3 Multi-Mode Microplate Reader
Alexander P Bye & Jonathan M Gibbins;

University of Reading and Simon J Lydford; Molecular Devices (UK) Ltd.
Platelets are small, anucleate blood

cells that mediate haemostasis by aggregating at sites of blood vessel injury
to form a thrombus (or clot) that limits
blood loss. When platelets respond
to vessel damage inappropriately this
can lead to thrombotic disease such
as heart attacks and ischaemic stroke.
Three main steps underlie thrombus formation; stage one is adhesion (platelets
attach to exposed matrix proteins in the
damaged vascular endothelium), stage
two is activation (receptor mediated
events such as shape change and secretion of chemical messengers) and stage
three is aggregation (platelet-to-platelet
adhesion). During platelet adhesion platelets are initially activated by collagen
via the glycoprotein VI receptor (GPVI)
and then a variety of secreted agonists
such as adenosine diphosphate (ADP)
and thromboxane A2 (TxA2) that activate G-protein coupled receptors
(GPCRs). These receptors couple to one
of two phospholipase C (PLC) isoforms
expressed in platelets; PLC or PLC2
and subsequently to the release of cal-
cium (Ca2+) into the cytosol from the

dense tubular system (DTS). Depletion
of Ca2+ from the DTS triggers an inux
of extracellular Ca2+ via a mechanism
known as store-operated Ca2+ entry.
Elevation of cyctosolic Ca2+ via these
mechanisms underpins all aspects of
platelet function, including adhesion,
shape change and aggregation. Therefore, understanding how different agonists modulate this critical regulator of
platelet function in health and disease
will guide development of novel, safe
anti-thrombotic drugs.
In this poster we show how it is feasible
to easily measure Ca2+ ux in human
platelets, a primary human tissue, in a
microplate format using the high afnity,
uorescent calcium indicator Fura2, AM.
We demonstrate that miniaturizing the
assay in 96-well half area microplates,
and using the exible liquid transfer
features of the FlexStation 3 reader
allows rapid and reliable measurement
of EC50 values for agonists and IC50 values for antagonists.
49
5/10/15 06:22

High-Throughput Assays for Characterizing the Viability and
Morphology of 3D Cancer Spheroid Cultures
Ben Haworth, Oksana Sirenko, Trisha Mitlo, Steve Luke,

Jayne Hesley & Windsor Owens
There is an increasing interest in using

three-dimensional (3D) spheroids for
modelling cancer and tissue biology
with the goal of accelerating translation
research. The goal of this study was to
develop high-content imaging and analysis methods to characterize phenotypic changes in human cancer spheroids
in response to compounds treatment
and to optimize spheroid assay protocols for higher throughput. Specically,
we optimized spheroid cell culture protocols using low adhesion 96- and 384well plates for three commonly used cell
lines, and improved the workow with
a one-step staining procedure that reduces assay time and minimizes variability. We improved imaging method
by using maximum projection algorithm
which allows combination of cellular information from multiple slices through
3D object into a single image that allows efcient comparison of spheroids
with different phenotypes. Image ana-
lysis method provides multi-parametric

characterization of single cell and spheroid phenotypes and can be extended
to sub-cellular analysis. We report phenotypic readouts of cell scoring, quantication of cell numbers expressing
different markers, measurement of cell
viability and apoptosis, as well as characterization of spheroid size and shape.
We assessed assay performance using
established anti-cancer cytostatic and
cytotoxic drugs, demonstrated concentration-response effects and measured
IC50 values. The 3D spheroid results
were compared to 2D cell cultures. Finally, we have screened a library of 119
approved anticancer drugs across wide
range of concentrations using 116HTC
spheroids. The proposed methods can
increase throughput and performance
of high-content assays for compound
screening and fast evaluation of anti-cancer drugs with 3D cell models.
50
5/10/15 06:22
P16: Ovizio
Differential Digital Holographic Microscopy (DDHM): a new
quantitative imaging technique that allows cell counting as
well as cell viability monitoring in a real-time, label-free and
non-invasive set-up
DDHM is applicable for monitoring
of suspension cells in bioreactors
as well as for screening of adherent
cells. Different versions of DDHM
have been created by OVIZIO to
meet the needs of our clients &
partners:
The iLine-F version is designed for
monitoring mammalian suspension
cell cultures in bioreactors without
the need for sampling thus avoiding
risks of contamination while facilitating further automation. Results are
available in nearly real-time and this
over the whole run as the OsOne
software plots the cell growth curves
live on the screen. Moreover, OsOne
also shows real-time images of the
cells, offering to the experienced
eye a convenient way to have a look
at his culture.
The iLine-M version allows the scanning of cells in culture vessels including -slides, multiwell plates and
multilayer vessels without staining
and detaching in the case of adherent cells. Monitoring adherent
cells directly in culture vessels with
DDHM delivers information not only
on cell number and conuence but
also on morphological parameters
of the cells. DDHM captures information on both intensity and optical
phase, at single cell level and combines these into a digital hologram.
Thanks to the optical phase information, DDHM can detect & quantify optical path changes (Quantitative phase contrast imaging) with a
nanometric accuracy.
51
5/10/15 06:22
P17: Perkin Elmer

Design and implementation of an automated PCR set-up
protocol for complex multiplex RT-PCRs on the JANUS liquid
handling station
Karen Dierickx PhD, Anne Vankeerberghen PhD, Hans De Beenhouwer MD /

Laboratory of Molecular biology, OLV-hospital, Aalst, Belgium
52
5/10/15 06:22
P18: PIKAROS
EYEMOL: An interactive tool for data driven Manipulation of
Molecules
Sbastien Maignan, Christophe Molina

Email: Christophe.molina@pikairos.com
EyeMol is an application for visualizing

and performing data-driven manipulations on molecule datasets. Its main
strength lies in the visualization of the
complete dataset at all times and its
simple manipulation (pan, zoom, rotate, etc). Experimental or in-silico
properties attached to the molecules
like IC50, MW, logP, among many
others, are easily used to color, search
and cluster the molecules. Each molecule can be annotated.
Typical use cases include :

- HTS analysis to identify and prioritize families and subfamilies for further studies
- Selection of molecules for backscreening
- Fine multiparametric analysis of a chemical series being optimized and identication of the best compounds to move
forward
- Fast selection of reactants for library
design
- Collaborative evaluation of molecules
during a meeting
- Notebook to keep up to date information on chemical series (like in a
spreadsheet)
Using EyeMol doesnt require molecular modeling knowledge, making
it an ideal tool for chemists and project managers.
53
5/10/15 06:22
P19: Sano Pasteur

Automation for bioformulation
Laure Cigolotti, Joel Morand, Laurent Quedeville, Hubert Venet,

Etienne Bultel, Manon Garello, Aure Saulnier, Sandrine Cigarini, Didier Clenet
Fully automated formulation screening, processing, monitoring and

data management solution was implemented to increase throughput
data generation, improve product
and process knowledge (DoE, QbD)
and insure seamless development
of product. A Core Module 3 (CM3,
Freeslate) was designed to build
large amount of formulations (screening of excipients) and monitor pH,
turbidity and color of solutions. Several analytical tools were linked to
the robot to monitor critical pro-
perties of formulated biomolecules

(DLS, DSF, NTA, HPLC, ). Data
management was fully integrated
to the workspace based on Freeslates laboratory robotics platform.
Stress programs were automated
(shaking, freeze/taw cycles, forced
degradation) and advanced kinetics
combined with statistical analysis of
data was used to rank formulations
in term of long term stability predictions. Such automation approach
aims to minimize risk in selecting formulation candidates.
54
5/10/15 06:22
P20: UCB
Accelerometry technology enables high-throughput studies
with mouse models of acquired epilepsy
Laure Cigolotti, Joel Morand, Laurent Quedeville, Hubert Venet,

Etienne Bultel, Manon Garello, Aure Saulnier, Sandrine Cigarini, Didier Clenet
Antiepileptic drug discovery has traditionally been done with the use of
rodent models where a single seizure
is induced in healthy animals. Such an
approach did not incorporate the underlying disease biology and was purely focused on symptoms (seizures).
Even though several drugs have been
successfully discovered, none of these
compounds is able to modify the disease or is effective in patients with
treatment resistant epilepsy. Thus new
animal models, characterized by spon-
taneous recurrent seizures, sharing

many features of human epilepsy are
increasingly used in drug discovery.
However, the use of such models is still
limited due to technological barriers in
monitoring spontaneous seizure in large
number of animals over prolonged periods of time. Here we describe the use
of a novel discovery platform (AccelEpi)
developed to accelerate the detection
process of epileptic seizures in mouse
experiments.
55
5/10/15 06:22
P21: University of Lige

Robotein: A robotic platform dedicated to high-throughput
protein production and analysis
Julie Vandenameele, Jolle De Meutter, Alain Brans,

Erik Goormaghtigh, Andr Matagne
Robotein is a technological platform built on competences and infrastructures available in the academic setting of two labs that offer a
complete structural biology portfolio: the Center for Protein Engineering (CIP, Universit de Lige, Belgium) and the Structural Biology and
Bioinformatics Centre (SBBC, Universit Libre de Bruxelles, Belgium).
Equipped with two Hamilton workstations (one EasyPick Microlab STARlet and one Microlab STAR), one
system for biomolecular interactions
analysis (Octet HTX by fortBIO
Pall Life Sciences), one system for
automated electrophoretic separa-
tion of RNA, DNA and proteins (LabChip GXII by Caliper Life Sciences
- Perkin Elmer), one high-throughput
protein arrayer (Marathon Classic Microarrayer by Arrayjet) combined with an infrared imager (Cary
620 FTIR imaging microscope by
Agilent) and two microplate readers
(Innite M200 PRO by TECAN), we
offer automated screening for optimal cloning and gene expression
in both bacteria and yeast, protein
purication and protein biochemical
and biophysical characterization, on
either a collaborative or service basis. (http://www.robotein.ulg.ac.be)
56
5/10/15 06:22
ELRIGfr conference
EXHIBITORS
57
5/10/15 06:22
Exhibition Hall
MicroTechniX
Horizon Discovery
Hamilton
Titian
Tecan
Conference Hall
buet
Hallway
HP
Posters Room
BMG Labtech
Perkin Elmer
Workshop Room
Floor plan: FOYER
58
5/10/15 06:22
HP Belgium
24
Osimis
23
PAA
Sopachem
22
21
ELRIGfr Quiz box
37
Andaman7
GC Biotech
17
36
Beckman
Molecular Devices
16
35
Zinsser
Labcyte
15
34
Argolight
Ovizio
14
33
SAFAS
Agilent
13
32
Widlcat
BioSPX
12
31
Lab Services
Xpert Automation
11
buet
Foyer
Floor plan: EXHIBITION HALL
59
5/10/15 06:22
Exhibitors List
Agilent (13)
Andaman7 (invited startup) (37)
ARGOLIGHT (34)
Beckman Coulter (36)
BioSPX (12)
BMGlabtech (G)
GC Biotech (17)
Hamilton (E)
Horizon (B)
HP Belgium (Quiz box) (24)
Labcyte (15)
Lab-services (31)
MicroTechniX (A)
Molecular Devices (16)
Osimis (invited startup) (23)
Ovizio (14)
Peak Analysis & Automation - PAA (22)
Perkin Elmer (F)
SAFAS (33)
Sopachem (21)
Tecan (C)
Titian (D)
Wildcat (32)
Xpert Automation (11)
Zinsser (35)
60
5/10/15 06:22
Agilent (Sponsor)
Stand #13
Agilent is a leader in life sciences,

diagnostics and applied chemical
markets.
The company provides laboratories
worldwide with instruments, services, consumables,
applications and expertise, enabling
customers to gain the insights they
seek.
Agilents expertise and trusted collaboration give them the highest
condence in our solutions.
Discover our energy and chemicals solutions: www.agilent.com/chem/energy

Learn more about Agilent:
www.agilent.com
61
5/10/15 06:22
Andaman7 (Invited startup)

Stand #37
Andaman7 is a mobile application

transforming healthcare communications into "Synchronized Health
Records"TM.
Create health records securely and
invite the people you trust to contribute.
Enhance communication and medical diagnostics using a comprehensive and personalized health record.
Making health collaborative, secure,
accessible...
And yes, its free for all.
www.andaman7.com
info@andaman7.com
+32 4 330 37 30
62
5/10/15 06:22
Argolight (Sponsor)
Stand #34
Argolight is specialized in uorescence quality management.
We offer a premium hardware &
software solution that provides a
complete suite of features with full
quality control integration for automation.
Unlike other solutions that lack stability and require time consuming calibration, Argolight delivers a combination or uncompromised user
friendliness and high effectiveness
across various uorescence systems.
Pharmaceutical, diagnostics and

biotech companies use our tools to
ensure the reliability of their measurements, while saving time on
their quality process.
As OEM, we also provide manufacturers with solution to monitor their
eets enabling cross-systems data
mining. Argolight is currently developing a partnership with NIST, the
USA national measurement standards laboratory.
www.argolight.com
contact@argolight.com
Tel: +33 (0)540 16 31 85
63
5/10/15 06:22
Beckman Coulter (Sponsor)

Stand #36
Beckman Coulter, bas en Californie
Fullerton, dveloppe et fabrique
des produits de haute technologie
pour les laboratoires de Routine, de
Recherche et d'Industrie avec pour
principaux objectifs d'Innover, d'Automatiser et de Simplier tous les
tests de laboratoire pour en rduire
les cots.
Plus de 200 000 systmes sont oprationnels dans le monde. Les pro-
grammes d'investissement dans la

mise au point de nouveaux systmes
sont en constante progression. Ce
qui explique l'avance remarquable
dans le domaine de la Robotiques
mais aussi en Gnomique, Centrifugation, Analyse Cellulaire, Caractrisation des Particules, ...."BR" Pour
plus d'information, consultez notre
site web: www.beckmancoulter.com
64
5/10/15 06:22
BioSPX (Sponsor)
Stand #12
BioSPX is a new company with a
strong focus on Life Science.
BioSPX is a full daughter company
of Beun - De Ronde, The Netherlands and has ofces in the Netherlands and in Belgium.
At BioSPX, its all about quality. In
our Quality Policy, we focus on delivering tailored solutions and a fast,
efcient but most of all dedicated
service to our customers. An intense
and open communication, the guarantee of both high-end products
and an excellent service and mutual trust are the key elements of
our quality. In this way we build and
maintain long-term relationships
with our customers.

Mission statement: We make your
innovation our goal!
BioSPX stands for the exclusive
distribution of high-end laboratory
solutions in the Netherlands, Belgium and Luxemburg.
We introduce new technologies
and innovations of existing systems.
We guarantee an optimal and
continued operation of your laboratory at all times.
You can count on an optimal technical support by our service team.
BioSPX B.V.
Bovenkamp 9 | 1391 LA Abcoude | tel: +31
(0)294 760088
Steenweg op/Chaussee de Ruisbroek 290b
1620 Drogenbos | Tel: +31 (0) 233 42274
65
5/10/15 06:22
BMGlabtech (Bronze Sponsor)

Stand #G
About BMG LABTECH The Microplate Reader Company
BMG LABTECH is a leading global
developer and manufacturer of innovative, high-quality, and reliable
microplate reader instrumentation.
BMG LABTECH has been committed to producing microplate readers for more than twenty ve years.
By focusing on the needs of the
scientic community, the companys
microplate readers have earned the
company the reputation of being a
technology leader in the eld. BMG
LABTECH has developed a wide
range of dedicated and multi-mode
microplate readers for life sciences
applications and high-throughput
screening. All BMG LABTECH microplate readers are Made in
Germany and are conceived, developed, assembled, and tested
entirely at BMG LABTECH headquarters in Germany. Since the establishment in Offenburg, Germany,
BMG LABTECH has expanded to
offer a worldwide sales and support
network with ofces in the USA, UK,

Australia, Japan and France.
The multimode microplate reader
CLARIOstar is BMG LABTECHs
latest innovation. The reader is
equipped with BMG LABTECHs
unique LVF monochromatorTM
technology, lters, and an UV/Vis
spectrometer. The triple technology offers high performance for a
variety of applications in all detection modes. Together with the new
Atmospheric Control Unit (ACU) the
CLARIOstar is able to provide the
physiological environment for any
cell type, making cell-based assays
more biologically relevant. The ACU
is entirely integrated into the reader
control software. Carbon dioxide
(CO2) and oxygen (O2) regulation
can be easily managed via the intuitive and easy to understand user
interface. Measurement results and
gas concentrations curves are displayed together over the time.
66
5/10/15 06:22
GC biotech (Sponsor)
Stand #17
GC biotech, based in Alphen aan
den Rijn, the Netherlands, distributes a wide range of life science
products. The emphasis lies on
instruments, software, kits and
reagents, developed with the aim
to simplify, accelerate and improve
life sciences research. GC biotech
combines the representation of
some of the most advanced US and
EU suppliers with in-house scientic and technical know-how. Since
November 2012 GC biotech is ISO
9001:2008 certied, that reects the
companys continued commitment
to the highest quality standards.

Over the years GC biotech has built
a strong sales team with academic
backgrounds in molecular biology.
They are supported by an engineering team with years of experience
in instrumentation and software. GC
biotech was founded in 2003 and
also manufacturers CleanNA. With
CleanNA, GC biotech develops
and manufacturers magnetic beadbased kits with a focus on high
throughput nucleic acid purication
technologies for DNA sequencing
applications
GC biotech B.V.
Leidse Schouw 2
2408 AE Alphen aan den Rijn
The Netherlands
www.gcbiotech.com
T: + 31 (0) 172 782 170
Info@gcbiotech.com
67
5/10/15 06:22
Hamilton (Bronze Sponsor)

Stand #E
Hamilton Robotics designs and manufactures fully automated robotic
systems for samples preparation and
storage. The products range from
unique, custom laboratory automation solutions (turnkey solutions)
on standard applications validated
through partnership programs with
renowned biotechnology companies as well as OEM solutions to the
top ten diagnostic companies.

Hamilton Robotics in one of the
leader of the world wide laboratory
robotic market and provides unique
innovations and performances to
your needs.
Hamilton Storage Technologies designs and manufactures cold storage
systems for biobanking and other
applications.
http://www.hamiltonrobotics.com/
http://www.hamilton-storage.com/
68
5/10/15 06:22
Horizon (Silver Sponsor)

Stand #B
Horizon Discovery is a UK Biotechnology company that combines deep
scientic experience in translational
research with a precision gene-editing platform incorporating rAAV,
CRISPR and ZFN technologies. The
company provides custom cell line
and in vivo model generation services for research and bioproduction
applications, molecular reference
standards, in vivo disease models,

and contract research and screening
services to over 1,000 organisations
engaged in research; drug discovery
and development; clinical diagnostics; and biopharmaceutical process
optimization. Horizon aspires to
provide science-driven research solutions that lead to better understanding of the genetic basis of disease
and better outcomes for patients,
from sequence to treatment.
www.horizondiscovery.com
info@horizondiscovery.com
Tel: +44(0) 1223 655 580
Fax: +44(0) 1223 655 581
69
5/10/15 06:22
Labcyte (Sponsor)
Stand #15
Labcyte, a global biotechnology
tools company, is revolutionizing
liquid handling. Echo Liquid Handler use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte
instruments are used worldwide
throughout the pharmaceutical industry, as well as by biotechnology
companies, contract research organizations, and academic institutions. Our customers work across
a wide spectrum of scientic research, including drug discovery,
genomics, proteomics, diagnostics, and personalized medicine.
Echo Software Applications
Echo Software Applications use

familiar terminology, interactive
graphics and wizards to provide a
research-friendly environment for
protocol creation and editing. This
drastically reduces the learning
curve and hands-on time. All protocols can be simulated before running live to validate each step.
Robotics Liquid Handling
Access Laboratory Workstation
The addition of an Access Laboratory Workstation expands the utility of

an Echo Liquid Handler into a fully automated system for high-throughput,
walk-away sample processing.
www.labcyte.com
Maria Savino, Account Manager
msavino@labcyte.com
70
5/10/15 06:22
LabServices (Sponsor)
Stand #31
Lab Services, Your independent
partner for integrated robot and laboratory equipment
If you choose Lab Services, you are
choosing high-quality, top-level service. For more than 20 years we have
made a name for ourselves with it.
Always keeping your needs in mind,
we offer user-friendly innovations

in laboratory automation. Such as
our in-house developed PlateButler Robotic Systems and recently
launched Heron, smart technology
for automation of a single microplate
device.
Generic info:
http://www.lab-services.nl/eng/
71
5/10/15 06:22
MicroTechniX (Silver Sponsor and Gala Dinner Sponsor)

Stand #A
Microtechnix main eld of activity
is integrated imaging analysis solutions, global layer managment,
quality & validation management.
We envision to create solution to
your needs with a partnership mindset.
The solution isnt only the automated equipment its also the integration into your lab processes .
The automated equipment requires
to be integrated, installed and validated to achieve your quality compliance level. An intuitive interface
to manage equipments applications

is also a key factor that
conducts us to develop the ICARUS
platform to manage your capacity
We are committed to provide support and continuous improvement
with our Life Cycle Management
package. Microtechnix has an expert
team and carefully selected partners
to endorse and deploy your
solutions. At the end its all about
improving the efciency and
throughput of your laboratory.
www.microtechnix.com
+32 (0)3 780 30 01
info@microtechnix.com
72
5/10/15 06:22
Molecular Devices (Sponsor)

Stand #16
How can you transform your protein
and cell biology research?
As one of the worlds leading providers of innovative analytical instruments and reagents for life science
research, pharmaceutical and biotherapeutic development, Molecular Devices is empowering scientists
to unravel the complexity of biological systems.
With over 130,000 placements in
laboratories around the world, their
total solutions are catalyzing brilliant
scientic research in the areas of:
Antibody Discovery
Cellular Imaging & Analysis
Contaminant Detection
Drug Discovery Screening
Electrophysiology
Gene Expression
Immunoassays
Protein Detection
Signal Transduction
Discover how Molecular Devices can
help you improve your productivity
and effectiveness, accelerate your
research, and discover new therapeutics faster.
Visit: www.moleculardevices.com
Contact: infoboxeu@moldev.com
73
5/10/15 06:22
Osimis (invited startup)

Stand #23
Our mission is to make image management and sharing in healthcare
and other sectors simple, powerful
and cost efcient through the use of
open source software.
Our product COHORTIS aims at taking the pain out of managing image
based medical trials.
It is a cloud based trial management

platform that integrates seamlessly
with Imaging Sites and Central Reading Labs through automation of
workows.
www.osimis.io
info@osimis.io
74
5/10/15 06:22
Ovizio (Sponsor)
Stand #14
OVIZIO designs, develops and markets 3-D & 4-D imaging systems and
sensors based on Differential Digital
Holographic Microscopy (DDHM).
OVIZIOs primary focus is the bioprocessing industry.
Our devices unify real-time quantitative imaging with a non-invasive,
label-free approach. Our technology
is applicable in R&D, Process Development and Production. Offering
tools that are convenient in use as
well as environment friendly, certainly contribute to a successful application throughout your organization.
OVIZIOs technology combines automation features with important reductions in cost, while improving on
quality and reproducibility. Typical
applications are: bioreactor monitoring of both: suspension and adherent cells, cell counting, assaying cell
viability and cell morphology.
OVIZIOs commercial partners are:
PALL Life Sciences
Applikon Biotechnology B.V.
Year of establishment: 2009
Number of employees: 14
Address: 100 rue du Bourdon, B-1180 Brussels, Belgium

Phone: +32 2 600 5090
E-mail: info@ovizio.com
Website: www.ovizio.com
Contact Persons:
Jol Henneghien, Business Dev. Manager: joel@ovizio.com,
Mobile: +32 479 43 43 99
Philip Mathius, CEO: philip@ovizio.com
Sector of Activity: BioPharma, Imaging, Diagnostics.
75
5/10/15 06:22
PAA (Sponsor)
Stand #22
Peak Analysis and Automation (PAA)
provides innovative solutions to laboratory automation - from scheduling
software and robotics to integrated
work cells.
Overlord3 is a powerful scheduling
and control software with over four
hundred drivers for common laboratory instruments including; liquid handlers, plate readers and incubators.
KiNEDx, BiNEDx and ProNEDx is a
family of laboratory robots and supporting peripherals.
These robots can normally be operated directly on the bench without

an enclosure and provide a cost effective means to improving your laboratory efciency.
Safel is an integrated workcell comprising an industrial robot, scheduling
control software and a range of instruments to perform the most complex
assays or sample preparation.
For further information contact

info@paa-automation.com,
visit our website:
www.paa-automation.com or give us
a call on +44 1252 37 3000 - One of
our engineers would be delighted to
talk to you.
76
5/10/15 06:22
Perkin Elmer (bronze Sponsor)

Stand # F
PerkinElmer is a global leader focused on improving human and environmental health, for the better.
To accelerate the understanding
of human health, we provide our
customers with the knowledge, expertise and solutions to better diagnose, treat and prevent disease.
Our innovative and integrated detection, imaging, software, reagents

and services solutions are accelerating discovery in core areas of research including epigenetics, genomics, cellular research, quantitative
pathology, in vivo imaging, biotherapeutics and informatics.
For more information see us at Booth F or visit

www.perkinelmer.com/lifescience
77
5/10/15 06:22
SAFAS (Sponsor)
Stand #33
SAFAS: PIONEERING IN SPECTROSCOPY AND ROBOTICS SINCE 1952
In 1952, tuberculosis was rampant
and SAFAS invented the worlds rst
oximeter, which saved a lot of lives,
enabled the rst heart catheterism,
and the rst articial kidney. In 1958,
SAFAS introduced the worlds rst
UV-Visible spectrophotometer with
grating monochromator; then in 1959
the worlds rst spectrouorometer
with 2 grating monochromators. This
beautiful vintage instrument, whose
innovations have become standards,
can be seen on our ELRIG booth
In 2000 it was the worlds rst multidetection microplate reader with grating monochromators, able to measure uorescence with cover opened,
with 100% AIR technology and continuously variable slits.
WINNER of the TROPHY of INNOVATION 2015 in Paris, SAFAS is an European manufacturer of highly innovative spectrophotometers (UV-Vis, IR,
AA), spectrouorometers, microplate
readers, and is proud to introduce
to ELRIG members the worlds rst
robotized multidetection microplate
reader with DIRECT INJECTION,
and TRANSFER TIME ZERO. Able
to measure simultaneously 10 stirred
78
10, quai Antoine 1er

MC98000 MONACO
cuvettes and a microplate, it is tted

with SAFAS revolutionary Double
Optical Plane concept, eliminates or
reduces most of interferences, and
draws Absolute Fluorescence Spectra. Quantum yields are measured in
integrating sphere, and temperature
control from 4C to 70C has gradient
mode and automatic desiccator. 1 to
15 auto-injectors with 6-way valves
have 0.1l accuracy, with auto-priming & washing. Reusable or disposable plates for 96x1l are available.
Autocalibrating on built-in standards,
it can be validated on certied standards in ALL its measurements modes, including uorescence and
bioluminescence great for Quality
Management!
Also available in TouchSnake version with a big 12 touchscreen on
a swivelling arm, it enables DIRECT
PIPETTING by a HAMILTON robot in
the microplate without transfer times,
and measures under the same environmental conditions (sterility, temperature, gas, moisture, etc), driven
by Ethernet Web Service.
SAFAS S.A. Manufacturer of High
Technology Scientic Instruments
since 1952/
Phone: +377 99 99 52 52
Fax: +377 99 99 52 50
e-mail: safas@safas.com
website: www.safas.com
5/10/15 06:22
Sopachem (Sponsor)
Stand #21
Sopachem strives to introduce new

and innovative technologies that
will help the scientic community
to accelerate its research work. We
serve our customers with the highest
standards of product knowhow, understanding their needs and applications.
During this ELRIGfr event, we will
focus on the best practices for biological sample storage. Indeed,

every sample that must be stored is
valuable. Loosing a sample due to
bad management of labeling is no
longer acceptable. Start using our
2D-coded tubes and be ready for
the scale up.
We have everything you need. Just
visit our booth.
www.sopachem.com/biobanking
79
5/10/15 06:22
Tecan (bronze Sponsor)

Stand #C
Tecan (www.tecan.com) is a leading

global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes
in the development, production and
distribution of automated workow
solutions for laboratories in the life
sciences sector. Its clients include
pharmaceutical and biotechnology companies, university research
departments, and forensic and dia-
gnostic laboratories. As an original

equipment manufacturer (OEM), Tecan is also a leader in developing and
manufacturing OEM instruments and
components that are then distributed
by partner companies. Founded in
Switzerland in 1980, the company
has manufacturing, research and development sites in both Europe and
North America and maintains a sales
and service network in 52 countries.
Contact: tecan.france@tecan.com
Tecan France S.A.S.U
6, Avenue du Chteau de Gerland
F- 69007 LYON
T +33 4 72 76 04 80
www.tecan.com
80
5/10/15 06:22
Titian (bronze Sponsor)

Stand #D
Titian Softwares Mosaic is the leading sample management software
suite, providing efcient and comprehensive management of compounds,
biological
collections,
reagents and standards. Designed
to streamline sample inventory,
tracking and ordering, in highthroughput biotech and pharma
laboratories, Mosaic provides the
preeminent solution to sample management, for rest-assured traceability and a seamless sample supply
chain.
As a modular software platform, Mosaic is scalable and provides exibi-
lity to support the critical sample

supply workows for all sizes of life
science organisations in industry and
academia. The latest version of the
software, Mosaic 6.0, also permits
extensive integration capability with
a range of automated stores and
dispensing systems for maximum
productivity and complete workow
management.
With an intuitive interface, requestors can select individual substances, plates or substance sets for
assay runs, and assay plate formats
can be dened and easily managed.
Routine assay sample requests can
also be congured as templates, saving valuable time.
81
5/10/15 06:22
Wildcat (Sponsor)
Stand #32
Wildcat laboratory Solutions est un
fournisseur de petits systmes dautomatisation et de consommables
pour la biotechnologie, la pharmacie
et les branches relatives ces industries, les petits laboratoires, la R&D,
les sciences de la vie et la biologie
molculaire.
La gamme de produits de la socit
comprend des systmes de gestions
de bouchons sur des tubes standards, des tiqueteuses de tubes ou
de plaques, des htels de plaques,
des tubes standards et cryotubes,

des microplaques et lms pour microplaques, des collecteurs acryliques, des lecteurs de codes barres
2D, des vaporateurs de solvants,
des applicateurs de codes barres et
bien plus encore. En se concentrant
sur son expertise technique et le dveloppement constant de ses produits, Wildcat laboratoire Solutions
sefforcent de proposer les solutions
dautomatisation de laboratoire les
plus appropries et les plus rentables.
www.wildcatlaboratorysolutions.com
Contact: Haakon Howard haakon@wildcat-ls.eu
82
5/10/15 06:22
Xpert automation (Sponsor)

Stand #11
Xpert automation is based on 30
years of experience in laboratory robotics.
We assist pharma research managers for tendering and monitoring
of achievement for their storage systems and biobanks.
Furthermore, Xpert automation
holds a patent on an innovative
technology capable of controlling
the distribution of few tenth of milligrams of powder.
In collaboration with industry representative Beta-testers, the company

has developed a robotic platform for
the direct production of stock solution into minitubes from solid compound, for libraries and screening.
All 1D and 2D identication features,
capping and labeling are integrated.
These features are also available into
a logistics platform.
XpertDose and XpertLogistics are
now available on the market.
Visit us on our booth into the exhibitors area (stand #11).
83
5/10/15 06:22
Zinsser Analytic (Sponsor)

Stand #35
Created in 1970 by Werner ZINSSER,
still General Manager of this privately
funded and hold German company,
ZINSSER Analytic has always been
committed in supplying instrumental
solutions , especially tailor-made robotics and consumables , to the laboratories.
The expertise of the company and his
60 employees are now well- known
and recognized nearly all around the
world. It is clearly the manufacturing
of customized robotic platforms , fully
applications oriented , and designed
to accelerate the samples preparation done in R&D, QC if not production departments working on:from
medium to high throughput chemical synthesis and complete catalyst
preparation, formulation studies of
products , such as lubricants, drugs,
polymers, solubility studies and polymorphism screening of new drugs,

soil and food contamination analysis,
protein crystallization ,and more generally speaking , any samples preparation involving liquids, solids and
viscous products , including handling,
weighing, mixing, heating and cooling, ltration , drying, titration , or
imaging steps before any analysis.
The members of ZINSSER Analytic
GmbH in Europe and the U.S.A or
their local distributors through other
countries stay at your disposal to
carefully hear your requirements regarding any process of more or less
complex samples preparation and
will be committed to suggest you
their solutions
Web Site: www.zinsser-analytic.com and

write to sales@zinsser-analytic.com
84
5/10/15 06:22
Evotec is a drug discovery alliance

and development partnership company focused on rapidly progressing
innovative product approaches with
leading pharmaceutical and biotechnology companies. We operate
worldwide providing the highest
quality stand-alone and integrated
drug discovery solutions, covering
all activities from target-to-clinic.
The Company has established a
unique position by assembling topclass scientic experts and integrating state-of-the-art technologies as
well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and
inammation.
Evotec has long-term discovery
alliances with partners including
Bayer, Boehringer Ingelheim, CHDI,
Genentech, Janssen Pharmaceuti-
cals, MedImmune/AstraZeneca and

Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include
partnerships with Boehringer Ingelheim, MedImmune and Andromeda
(Teva) in the eld of diabetes, with
Janssen Pharmaceuticals in the eld
of depression and with Roche in the
eld of Alzheimers disease.
Evotec is built on integrated drug
discovery know-how of more than
15 years and is a leading player in
the drug discovery eld. The Companys headquarters are located
in Hamburg, Germany. Additional major operations are based in
Abingdon, UK, Gttingen, Munich,
Germany, San Francisco, Princeton
and Branford, USA. Evotec has more
than 600 employees worldwide.
For more information please visit

http://www.evotec.com/
or contact info@evotec.com.
85
5/10/15 06:22
ELRIGfr
MISSION AND OBJECTIVES
ELRIGfr is a Not For Prot special interest group focused on the use of
automation, robotics and instrumentation in the laboratory and also on
the wider applications of laboratory
automation.
Our organisation is run wholly by volunteers.
Our membership consists of scientists, researchers, engineers, developers and business-people who are
interested in robotics, automation
and associated technological developments in this eld.
Our primary objective is to provide an open communication forum
for users and vendors, within which
members can be educated, share
information and experience and
network with other members.
Our primary means of achieving this
is to organise Meetings and Conferences in which our members' experiences of automation are presented
and at which relevant vendors exhibit their latest technology.
Our aim is to provide world-class
meetings and conferences which are
accessible to all.
In order to meet our open-access
aims, we operate a business model in which delegate access to our
meetings is Free of Charge. We
aim to cover the cost of staging our
events from the contributions of the
exhibitors and Sponsors.
In order to offer top-class meetings,
we operate an open policy of collaboration with other well-established
and respected professional societies, to add both breadth and depth
to our offering.
Additional objectives include:
- Providing specic training and
educational programs
- Support for new companies in our
eld
- Awards recognising achievement
and/or innovation in our eld
- Where possible provide Grants /
Sponsorship for specic projects of
relevance
- Ultimately, we aim to promote the
health, growth and sustainability of
our industry.
86
5/10/15 06:22
Who are we?

Olivier Casamitjana
President Elrig.fr
Engineer by training in biological

sciences, Olivier Casamitjana acquired 18 years of experience in the
pharmaceutical industry. Successively at Pzer and Solvay-Fournier,
Olivier worked in the domains of assay development, high throughput
screening and management of
sample patrimony. Then Olivier worked within Sano during 10 years.
He was successively project leader
of large automated stores for compound management and of a LIMS
implementation to manage the inventories, the workows and the robotics interfaces.
Olivier Casamitjana has been the
global coordinator of the Sano
compound management group, notably in charge of the strategy and
key partnership and led the Toulouse Sample Management group

during 8 years.
More recently, Olivier held an MBA
program from Toulouse Business
School and led, as a deputy, a technological & translational platform
(integrated Drug Discovery), aiming
at developing external business.
Since April 2015, he leads the screening and compound management
department of Evotec France and
he is part of the senior leader team
in charge of the companys strategy.
Active member of the club robotique since 1999, Olivier has been
elected in June 2013, president of
Elrigfr (European Laboratory Robotics Interest Group Francophone).
87
5/10/15 06:22
Frederic Ausseil
Vice President Elrigfr (Treasurer)
Frederic Ausseil is the current manager of the assay automation and HTS
team of the Pierre Fabre CNRS research and service unit 3388 in Toulouse.
Trained to automated biology in the
bioMrieux company and the Claude
Bernard University (Lyon, France)
where he received his PhD in biological engineering, Frederic has contributed since 1996 to the development
of HTS at Merck KGaA and Pierre Fabre companies as well as in the CNRS
(rst French academic research institute). Concurrently, he created with
other CNRS scientists the Plateforme
Intgre de Criblage de Toulouse
(PICT) bringing together the Toulouse
academic screening facilities.
Member of the Club Robotique
since 1997, he believes that its evolution to ELRIG.FR will turn it into a very
benecial tool for technological and
scientic exchanges within the lab automation community.
Jacques Hamon
Vice President Elrigfr
Jacques Hamon is senior investigator

at the Novartis Institutes for BioMedical Research in Basel, Switzerland.
He is currently leading a new initiative
called FAST lab (Facilitated Access to
Screening Technologies) aiming to
provide easy access to all screening
technologies to research labs inside
Novartis and potentially outside to
Academia. Over the past 9 years, he
has led and developed the Basel in
vitro safety pharmacology proling
activities designed to predict and
mitigate potential adverse effects of
drugs under discovery stages for all
the Novartis projects globally. Previously, he led a biochemistry laboratory, setup and managed the screening capabilities and became project
leader at Pzer in Fresnes, France
(formerly Jouveinal and Parke-Davis
research center). Jacques received an
engineering degree in Organic chemistry in 1993 from the Ecole Nationale Suprieure de Chimie de Montpellier and completed his PhD in life
sciences in 1996 from the University of
Montpellier, France. His main interest
is to contribute to the optimization of
the early drug discovery processes
for the identication of leads, clinical
candidates and ultimately drugs with
better pharmacological proles.
88
5/10/15 06:22
Olivier Nosjean
Olivier Nosjean joined Servier in

1999 after obtaining his PhD in Biochemistry. He since then has been
acting within the internal service
platform dedicated to molecular and
cellular assays, setting-up the Laboratory of Assay Development and
HTS and, more recently, supervising
the set-up of two novel laboratories,
dedicated to Stem Cells for one and
to Chemogenetics for the other. As
a Director of Department, Olivier
Nosjean is coordinating the activity
of these three labs, and he is actively
involved in the understanding of the
molecular and cellular mechanisms
of action related to the various drug
discovery projects of the company.
His activities include reaching out
external experts, and participating
in collaborations with academic as
well as private institutions.
Benot Fouchaq
Benoit has been responsible for the

HTS and the proling activities at
Cerep for 10 years. In 2010, Benoit
heads innovation group which provide tailor made scientic program
according to clients needs. He is
also in charge of implementing the
lean process for reducing the time to
market of new products and stimulating innovation for drug discovery
on the 3 sites, Poitiers, Seattle and
Shanghai. Through his position, Benoit is a privileged contact for clients
and providers worldwide.
He holds a Doctorate degree in enzymology from the University of Paris XI as well as an Executive Master
in Business Administration from the
HEC business school.
89
5/10/15 06:22
Pascal Silversmet
Relationship & Sponsoring
Pascal Silversmet joined GlaxoSmithKline in 1995 after obtaining

his graduate in biochemistry. He
took over diverse responsibilities in
labs of R&D department. In 2000
he joined automation group and
was responsible for developing automated systems in image analysis
and microscopy eld.
Currently Pascal lead the unit Engineering Automated Systems for
Laboratory (EASy.Lab) that covers
the implementation strategy of automation transversally in R&D department of GSK Vaccines Belgium
and North America. His team activities include robotics, liquid handling
and image analysis automated
systems development as well as deploy and share the automation expertise across the organization in a
partnership mindset.
Haakon Howard
Elrigfr Advisory / Fundraiser / Events
Since 1991 Haakon has worked as an

experienced Sales Director and General Manager within the Life Science
community, with an analytical and
scientic approach to strategic planning. Since 2007 Haakon has started
his own company, acting as a consultant, and selling small bench top laboratory automation, and is now living in France.
Haakon has been an active member
of Elrig UK for 8 years and has been a
key driver in the setting up of ELRIGs
awards scheme, and in nding ways
for Elrig UK to support the industry.
Haakon has been instrumental in the
creation of Elrigfr=, and hopes he is
able contribute to make it the success
that it should be.
90
5/10/15 06:22
Natalio Vita
General Secretary Elrigfr
Natalio is a Medical Biochemist who

obtained his PhD in Biochemistry
in 1984 at the University of Buenos
Aires (Argentina). He was professor
of Biochemistry in the School of Medicine of the same university until
1985.
He joined Sano in January 1986
and he continued working on the recombinant human growth hormone
developed by Sano in these years.
Some years later, he actively participated in the cloning, purication,
characterization and development
of interleukin-2 and interleukin-13
and their receptors.
In the 90s the team developed interesting tools for the expression
cloning of receptors that have been
used with success for cytokines (IL13) and also neuropeptides such as
neurotensin and CRF.
From 2000 to 2004, Natalio was
Head of the Cardiovascular Bioche-
mistry group in Montpellier. The

team worked on the validation of
different targets involved in heart
failure and in the development and
characterization of cardiomyocytes
generated from embryonic stem
cells.
From 2004 to 2010 he was Scientic Attach in Discovery Research
Scientic Direction. For the last years
and until retirement he was Cluster
Leader in E2C (Early to Candidate
Unit) in Sano, coordinating projects
associated to Immuno-inammation
and Infectious Diseases.
Actually he is Editor of the Pre-Clinical Research Section in the JNHA
(The Journal of Nutrition, Health and
Aging).
Natalio is co-author of patents and
more than 60 articles covering different scientic areas like immunochemistry, biochemistry, cytokines, receptors, infection and immunity.
91
5/10/15 06:22
Gala Walking Dinner Sponsored by
A tasty Belgian menu spread over

tiny stalls will be offered.
The Gala Dinner will be held at an
amazing place:
Les Halles Saint Gry,
Place Saint-Gry 1, 1000 Brussels.
Its 15 to 20 minutes walk from the

Brussels Sheraton Hotel.
From the main entrance of the hotel, take to the right and follow the
Boulevard Adolphe Max and straight
away until Rue Jules Van Praet.
Pre-registration to the Gala dinner
is mandatory.
92
5/10/15 06:22
93
5/10/15 06:22
E X T R A O R D I N A RY C H O C O L AT E
94
5/10/15 06:22
Brussels Airlines welcomes the ELRIGfr 2015 conference
5/10/15 06:22
HPElitePad1000G2
HealthcareTablet
Integrate workows, access and update healthcare

information systems, improve scientic research in
medical environment with the HP ElitePad 1000 G2
Healthcare Tablet, a Windows 8.1 solution designed
in tandem with healthcare professionals.
It has industry-leading security features such as a
certied smart card reader, HP Client Security, HP
BIOS Protection, and Trusted Platform Module
(TPM) and full disk encryption.
ELRIGfr would like to thank HP Belgium for their contribution of two HP

ElitePad 1000 G2 Healthcare Tablets. One unit will be oered to the most
innovative Poster and the other will be drawn among the ELRIGfr Brussels
conference 2015 quiz participants.
5/10/15 06:22
SAVE THE DATE!

Next ELRIGfr conference
13-14 April 2016

Drug Discovery &
Phenotypic Screening
Rennes, France
97
5/10/15 06:22
Elrigfr would like to thank their Founding

Sponsors who have helped make all events
possible and for their continued support:
5/10/15 06:22

Booklet ELRIGfr Brussels 2015

Uploaded by

Document Information

Copyright

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Booklet ELRIGfr Brussels 2015

Uploaded by

Copyright:

ELRIGfr conference

ELRIGfr Committee members wish to

Special thanks to:

(& Gala Dinner Sponsor)

Booklet designed by Kevin Lewkowicz,

priate economic model? Your voice

- Lab automation technologies

After the scientic presentations,

I would also like to send a few words

Natalio Vita - ELRIGfr

From 2004 to 2010 he was Scientic

From 2000 to 2004, Natalio was

Pascal Silversmet joined GlaxoSmithKline in 1995 after obtaining

After a PhD in fundamental research

Jean-Marc Josse Elrigfr

PhD in Molecular Biology and Plant

Maria Savino - Elrigfr

The marketing and logistics aspects

We would like to warmly thank:

Chocolatier Neuhaus for the tasty present in the Welcome Bags

Welcome attendees (pastries, tea, coffee, fruit juices)

Introduction by the ELRIGfr President

How automation changed the way we analyse

Development of a High-Throughput Screening

New approach for Bioanalytical Sample preparation

Pause: Exhibition & Posters

The HCS Platform at the Institut Pasteur of Lille

Snapshots Sponsors: Beckman, Agilent, PAA, Ovizio,

Walking Lunch: Exhibition & Posters

Biobanks: automate or die

Biobank automated workows for DNA extractions

Pause: Exhibition & Posters

Automated sample handling in a forensic

Sample Processing and Storage - RiskManagement

Silver Sponsor: Next generation of genetic models

Conseil dadministration ELRIGfr

M. Bruinenberg, LifeLines, The Netherlands

Welcome attendees (pastries, tea, coffee, fruit juices)

Validation of a Focused Chemical Library dedicated to

Bag3, a multifaceted protein playing a central

Role of methionine sulfoxide reductase (MsrA) in

Pause: Exhibition & Posters

B. Favaloro, Univ. Pescara

Multi-application Imaging Systems Management

Walking Lunch: Exhibition & Posters

Workshop Voice of Customer All members are invited

Quiz Sponsor winner & Poster awards announcement, closing session

LAB PROCESSES AUTOMATION

Prof. Dr. Frank Gudermann, University of

Some working processes in biotechnology are well automated, other

Different levels of automation of the

Examples of cell concentration determination and the measurement of

Since March 2008 Prof. Gudermann

the marketing and sales structure for

From 2001 to 2005 Dr. Gudermann

Development of a High-Throughput Screening

Vanessa Jully, GSK vaccines, Rixensart, Belgium

sorption. Highly reproducible adsorption capacities and adsorptive

During my master degree in Pharmacy, I had the opportunity to work

Juergen Siepmann. Since two years,

New approach for Bioanalytical Sample

The increasing use of micro-sampling techniques in animal experimentation is challenging the

Nevertheless we had to overcome

Our choice is to us the Echo 550

Dipl. Ing. Martin Kapps

Dilp. Ing. Martin Kapps is leading

The HCS Platform at the Pasteur Institute